Stockwinners Market Radar for June 21, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 82K shares of Block today

20:06 EDT Cathie Wood's ARK Investment bought 146.7K shares of TuSimple today

19:01 EDT Calavo Growers names Danny Dumas to lead Grown segment - Calavo Growers "announced that Danny Dumas has been named Senior Vice President & General Manager Calavo Grown, filling the role held by Robert Wedin who is retiring after 49 years with Calavo."

18:26 EDT Goodyear Tire CEO: Business remains strong - In an interview on CNBC's Mad Money, Richard Kramer said Goodyear's goal by 2030 is a 100% sustainable tire. He noted cash flow in Q1 is usually negative as inventory is built, but this is standard in the industry. Material costs continue to increase, he added, and the company has to recoup them via price hikes. He feels this trend will likely level off in the near future.

18:24 EDT User reports indicate problems at Verizon, Downdetector says - Reference Link

18:03 EDT Pacific Woodtech to acquire LP Building's EWP business for $210M - LP Building Solutions announced an agreement with Pacific Woodtech to acquire LP's Engineered Wood Products business for $210M. The acquisition includes LP's laminated veneer lumber and I-joist manufacturing facilities in Wilmington, North Carolina; Red Bluff, California; and Golden, British Columbia, Canada, associated timber license assets, and the SolidStart brand. The completion of this transaction is subject to customary closing conditions and regulatory reviews and is expected to occur in the third quarter of 2022. "We believe that Pacific Woodtech is well positioned to invest in and grow the SolidStart brand, and its acquisition of LP's EWP business marks another important step in LP's ongoing strategic transformation," said LP Chair and Chief Executive Officer Brad Southern. "We will work with Pacific Woodtech to ensure a smooth transition for our EWP employees, customers, and suppliers. I want to express my sincere thanks to the entire EWP team for their patience and professionalism throughout this process. I wish them all the best moving forward."

17:50 EDT Enviva sees Q2 sales volumes up roughly 20% - The company expects Q2 volumes to increase approximately 20% over first-quarter 2022 actuals, as short-term supply chain issues continue to resolve. "Continued global commitments to the energy transition combined with the current geopolitical backdrop are creating a highly constructive pricing environment for near-term deliveries and long-term contracts at favorable headline pricing levels not previously seen," said CEO John Keppler. "Our sales and marketing teams in Europe, Japan, and the United States are making great progress toward executing new long-term agreements and converting previously announced memorandums of understanding to binding take-or-pay off-take contracts. Given the continuing structural shortage in wood pellet supply that remains in our industry, where long-term demand continues to outstrip supply capacity, there has never been a better time to be in this business and we are excited to be positioned for highly accretive, durable growth."

17:04 EDT Investor in AIkido Pharma urges board to sell assets, return capital - Shalom Auerbach, a stockholder of AIkido Pharma owning approximately 3.8% of its common stock, issued the following letter to stockholders of AIkido Pharma Inc.: "Dear Fellow Stockholders: I am a significant stockholder of AIkido Pharma Inc., beneficially owning approximately 3.8% of the Company's outstanding common stock. Earlier this month on June 7, 2022, I sent a public letter to the Company's board of directors (the "Board") laying out my concerns about the Company's abysmal stock performance, poor corporate governance and lack of accountability to stockholders. I also asked that the Board and management either redirect the Company towards setting out a clear business plan to create stockholder value while firmly establishing accountability to investors, or to return capital to stockholders. Before and after sending my prior letter, I attempted to privately engage with the Board and management on the need for significant change at the Company. Unfortunately, the Company's current directors and management do not appear to be interested in true engagement on stockholders' concerns... I believe that the Board and management have shown a glaring disregard for the best interests of stockholders, and have not given any genuine indication that they intend to change course. I fully expect that, so long as the current directors and management remain in place, management will continue to spend stockholder money on risky and illiquid investments, far outside the Company's purported core biotechnology business,4 and the Board and management will continue to pay themselves handsomely in cash at the expense of stockholders. The exclusively cash-based compensation of the Company's executives and directors for 2021, and directors' minimal stock ownership of less than 0.25% of the shares outstanding, show a clear misalignment with the best interest of stockholders."

17:01 EDT Southern First Bank opens new headquarters in Greenville, SC - Southern First Bank announced the opening of its new corporate headquarters at 6 Verdae Boulevard in Greenville, S.C. "Southern First Bank was founded in Greenville over 22 years ago. We are excited to celebrate the opening of our new headquarters as this investment is a message to the community and throughout the Southeast that our team is committed to strong relationships, progressive technology, and a servant heart culture. We will continue to grow one client at a time and look forward to continuing this journey for the next 22 + years," stated Art Seaver, CEO of Southern First.

16:50 EDT Ra Capital Management increases passive stake in Wave Life Sciences - Ra Capital Management disclosed an increased stake in Wave Life Sciences to 17.27M shares. The filing does not allow for activism. Shares of Wave Life Sciences are up 11.7% afterhours at $2.30.

16:33 EDT Matthews to acquire Olbrich and R+S Automotive for $45M - Matthews announced that the company signed an agreement to acquire German based engineering firms, Olbrich and R+S Automotive, for EUR 43M, or $45M. Olbrich and R+S Automotive have combined annual revenues in excess of $100M. Headquartered in Bocholt, Germany, Olbrich is a production and intelligent equipment manufacturer, specializing in purpose-built rotary processing equipment, including equipment used in the manufacturing of dry and wet electrodes for lithium-ion batteries and components for hydrogen fuel cells used in electric vehicles, with additional strong positions in Specialty & Pharma, Packaging and Home & Decor. R+S Automotive is a specialty engineering services provider of automation, plant and tooling concepts for automotive manufacturing companies around the world. The closing of the transaction is subject to certain regulatory authority approvals, which is expected to be timely secured in July.

16:32 EDT ViaSat gets shareholder approval for acquisition of Inmarsat - Viasat "announced that, at its Special Meeting of Stockholders, it received the necessary stockholder approvals for the proposed acquisition of Inmarsat. Viasat continues to expect the transaction to close in the second half of calendar year 2022, subject to the receipt of certain regulatory approvals and clearances and the satisfaction of other customary closing conditions."

16:30 EDT Delek US announces special dividend of 20c per share - The dividend is payable on July 20, 2022 to shareholders of record on July 12, 2022.

16:25 EDT Avnet announces strategic collaboration with Amazon Web Services - Through a new global strategic collaboration agreement, Avnet (AVT) and Amazon Web Services (AMZN) are focused on helping Original Equipment Manufacturers of IoT solutions accelerate their time to market. This multi-year, joint investment will enable Avnet's IoTConnect Platform to deliver the breadth and depth of AWS' portfolio of services-creating a scalable, secure platform that preconfigures AWS' services for application-specific usage. This strategic collaboration provides Avnet's IoTConnect Platform with access to AWS' portfolio of services, including IoT, machine learning, analytics, and compute services. Avnet customers will soon have access to an aggregated IoT development experience across AWS services, including AWS IoT Core, AWS IoT Greengrass, FreeRTOS, AWS IoT Analytics, and AWS IoT SiteWise.

16:22 EDT MarketWise to join Russell 2000 Index on June 27 - MarketWise announced it is set to join the broad-market Russell 2000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, according to FTSE Russell postings in early June . Inclusion in the index will take effect after the U.S. market opens on June 27. Mark Arnold, Chief Executive Officer of MarketWise, commented, "We are pleased to be included in the Russell Index as this is another milestone for Marketwise. Membership in this index is an important step to increasing confidence from the investment community, while raising visibility and further solidifying our company in the public markets."

16:17 EDT Universal Logistics announces final results of self-tender offer - Universal Logistics announced the final results of its modified "Dutch auction" tender offer to repurchase up to 100,000 shares of its outstanding common stock, which expired at 5:00 p.m., Eastern Time, on Wednesday, June 15. In accordance with the terms and conditions of the tender offer, the company has accepted for purchase a total of 164,189 shares of its common stock, representing approximately 0.62% of the company's issued and outstanding shares, at a final purchase price of $28.00 per share. Payment for the shares accepted for purchase under the tender offer will be made promptly, at a total cost to the company of approximately $4.6M, excluding fees and expenses related to the offer. The company expects to have approximately 26,277,549 shares of its common stock outstanding immediately following consummation of the tender offer. The total amount of shares purchased in the tender offer reflects the company's right to increase the tender offer by up to 2% of its outstanding shares and includes 5,000 shares tendered by a director of the company, H.E. "Scott" Wolfe.

16:15 EDT Aziyo Biologics appoints C. Randal Mills as interim CEO - Aziyo Biologics announced Aziyo co-founder C. Randal Mills, has been appointed interim president and CEO. Ronald Lloyd will step down from these positions but will remain with the company through the end of the third quarter to assist with the transition. Aziyo co-founder Kevin Rakin has also assumed the role of executive chairman.

16:12 EDT CarLotz announces closure of 11 dealership stores - CarLotz announced the closure of 11 dealership stores, or hubs, as part of a strategic review of the business, with cash preservation and future profitable growth as key determining factors. In addition, three locations with executed leases will not be opened. The company will focus on growing the remaining hubs. The company is closing these 11 hubs for retail sales on June 21 with all hub closing activities to be completed by July 8. The closures will result in an estimated workforce reduction of 25% to 30%. The company estimates the closures should reduce loss from operations by approximately $12M to $13M on an annualized basis. This estimate assumes, among other things, that the company will be unable to sub-lease any locations. The company is evaluating opportunities to sub-lease or assign certain locations to interested parties. If we are able to sub-lease or assign the leases associated with the 11 hubs and the three unopened locations, the company estimates an additional savings of $7.5M to $8.5M in occupancy costs per year. In addition to the anticipated reduction in loss from operations going forward, the company believes the hub closures should provide additional working capital of approximately $10M, as inventory is liquidated based on anticipated sale prices at these locations. This anticipated increase in liquidity will be partially offset by one-time severance costs of approximately $500,000 to $600,000. The company estimates one-time non-cash charges of $2M to $5M associated with the impairment of lease assets and $5M to $6M associated with the impairment of other fixed assets. Other future costs, such as contract termination costs, are yet to be determined and will be dependent in part on current lease negotiations.

16:10 EDT First Watch Restaurant appoints Bumble CPO Stephanie Lilak to board - First Watch Restaurant (FWRG) announced the appointment of Stephanie Lilak, chief people officer of Bumble (BMBL), to its board of directors, effective June 17. Lilak will serve as a member of the audit committee and the compensation committee of the board.

16:07 EDT Galapagos to acquire CellPoint, AboundBio for EUR 125M upfront - Galapagos, CellPoint and AboundBio announced that both companies have entered into definitive agreements with Galapagos. Through the acquisition of CellPoint and AboundBio, respectively, Galapagos gains access to a point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Under the terms of the agreements, Galapagos is to acquire all outstanding shares of CellPoint and AboundBio in an all-cash transaction against payment of an upfront amount of EUR 125M for CellPoint, with an additional EUR 100M to be paid upon achievement of certain milestones, and against payment of an amount of $14M for AboundBio. The transactions have been fully executed and the acquisitions were consummated earlier.

16:06 EDT Arcellx names Maryam Abdul-Kareem as General Counsel - Arcellx (ACLX) announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma (KNTE) and AstraZeneca (AZN). At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.

16:02 EDT Bowman Consulting awarded $15.9M contract - Bowman Consulting "announced that the Illinois State Toll Highway Authority awarded the company a $15.9M professional engineering services contract to provide construction management services for the roadway widening and reconstruction on the Tri-State Tollway between Ogden Avenue and Cermak Road. The contract includes all construction management, oversight and documentation required to complete the work. Bowman, along with its 10 subconsultants, will provide construction engineering services to oversee the widening and reconstruction of a 1.7-mile section, with a projected construction cost of more than $100 million. Bowman's portion of this construction project is anticipated to begin in Fall, 2022."

16:00 EDT CarLotz trading halted, news pending

15:22 EDT Novartis to petition CAFC on Gilanya dosing regimen patent - Novartis announced that the U.S. Court of Appeals for the Federal Circuit, or CAFC, issued a new, negative decision regarding the validity of U.S. Patent No. 9,187,405, covering a dosing regimen for Gilenya. Novartis plans to file a petition seeking further review of this decision. "In August 2020, the U.S. District Court for the District of Delaware issued a favorable decision in the Gilenya patent litigation and a permanent injunction was granted against HEC Pharma until the expiration of the '405 patent in December 2027 (including pediatric exclusivity). HEC Pharma was the only remaining Abbreviated New Drug Application (ANDA) filer challenging this patent. In January 2022, a three-judge panel of the CAFC issued a decision upholding the validity of the dosing regimen patent. HEC filed a petition for rehearing with the CAFC, which today issued a decision from a modified panel reversing its previous decision and now finding the patent invalid. Novartis intends to vigorously defend the validity of the patent and is considering all available options, including current plans to seek review of this decision by the full CAFC, a process which may take several months. Previously, Novartis entered into settlement agreements with a number of ANDA filers. Those ANDA filers will be able to launch a generic version of Gilenya on an agreed upon date that is prior to the expiration of the dosing regimen patent or earlier under certain circumstances. As the formal mandate closing the appeal process has not been issued from the CAFC, the permanent injunction granted against HEC remains in place and Novartis believes that HEC and other ANDA filers are not permitted to launch a generic version of Gilenya at this time," the company stated.

14:53 EDT Crispr Therapeutics down 11% as Virtual Innovation Day continues - Crispr Therapeutics began its "Virtual Innovation Day" presentation at 2 pm. In afternoon trading as the event continues, shares are down $7.88, or 11%, to $62.13.

14:09 EDT BOK Financial names Mike Rogers chief accounting officer - BOK Financial Corporation has named Mike Rogers, CPA, as chief accounting officer effective upon the retirement of John Morrow in September 2022. The appointment came after the announcement that Morrow was retiring after 30 years with BOK Financial. Rogers is an accounting and finance professional with almost 30 years of experience including half his career in public accounting, reaching the position of audit partner at a regional firm. He has extensive public company experience with years of SEC reporting and initial public offerings. "Our company was incredibly fortunate to have John Morrow as our CAO. We can't thank him enough for his dedication to BOK Financial," said Steven Nell, chief financial officer for BOK Financial.

13:46 EDT Blizzard says 'World of Warcraft: Dragonflight' available later this year - Blizzard Entertainment announced that "Dragonflight," the next expansion to the massively multiplayer online role-playing game "World of Warcraft," is now available for pre-purchase at www.worldofwarcraft.com and is set to launch later this year. "We are thrilled to share that we'll be bringing our next expansion to players later this year. Dragonflight is a return to Azeroth, and the freedom and exploration that World of Warcraft is known for," said Executive Producer Holly Longdale. "This is your chance to get up close and personal with the rich history of the storied Dragon Isles, and to immerse yourself in the high-fantasy at the core of the Warcraft universe."

12:59 EDT Amazon announces AWS Center for Quantum Networking - In a blog post, Amazon Web Services announced the AWS Center for Quantum Networking with a mission to address fundamental scientific and engineering challenges and to develop new hardware, software, and applications for quantum networks. CQN will complement the advanced quantum science and engineering efforts already underway at the AWS Center for Quantum Computing and the Amazon Quantum Solutions Lab. "Like quantum computers, quantum networks are still at an early stage of development, with many outstanding challenges remaining before their full potential is reached," the company said. Through our investment in quantum research and workforce development, the AWS CQN aims to bring quantum network-enabled advances in privacy, security, and computational power one step closer to our customers." Reference Link

12:32 EDT Hoth announces HREC approval in Australia for next phase of BioLexa trial - Hoth Therapeutics announced it has received approval by the Bellberry Human Research Ethics Committee, or HREC, in Australia to initiate the next phase of its BioLexa trial for patients suffering with atopic dermatitis. "Receiving clearance is a critical milestone in our clinical trial in Australia. Hoth's scientific advisors believe that Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the clinic," the company stated.

12:03 EDT FedEx makes strategic investment, enters alliance with FourKites - FedEx and FourKites announced a strategic alliance that will provide businesses with new, more robust real-time visibility capabilities to help solve their most pervasive supply chain challenges, become more efficient, and unlock new growth opportunities. Events like the COVID-19 pandemic, ongoing geopolitical issues, port congestion, and other global disruptions have revealed the complexities in keeping interconnected supply chains around the world up and running. FedEx and FourKites are collaborating to make supply chains smarter by bringing comprehensive and highly granular visibility into multi-modal and multi-carrier operations with the deep network and rich insights of their combined networks. FourKites' real-time visibility platform has integrated intelligence at every point of the supply chain, and currently supports 2.5 million shipments a day, connecting the supply chains of 50% of Fortune 500 companies. Through this collaboration, FourKites will be using its machine learning and artificial intelligence capabilities with data insights from the FedEx network - which reaches more than 220 countries and territories, linking more than 99 percent of the world's GDP, through more than 16.5 million shipments daily - to create a new end-to-end supply chain intelligence platform called FourKites X. FourKites X will provide tools and insights to help large shippers and logistics providers mitigate the impacts of sustained challenges via a suite of offerings ranging from dynamic planning and pre-shipment, to enhanced visibility and proactive alerts, to supply chain optimization insights. To support this alliance and the launch of FourKites X, FedEx has made a strategic investment in FourKites. FedEx Dataworks, a business unit in FedEx focused on making supply chains smarter through a powerful data science approach and machine learning capabilities, will support FourKites' development of the new platform, FourKites X, that will help give customers deeper actionable insights, more accurate ETAs, and more intelligent supply chains to reduce supply chain volatility, and improve top-line growth.

12:00 EDT Grove falls -13.0% - Grove is down -13.0%, or -$1.30 to $8.70.

12:00 EDT Revlon rises 18.2% - Revlon is up 18.2%, or 68c to $4.41.

12:00 EDT Convey Health rises 138.5% - Convey Health is up 138.5%, or $5.99 to $10.30.

11:40 EDT MedTech Acquisition Corporation (Units) trading resumes

11:39 EDT Zhong Yang Financial Group Ltd trading halted, volatility trading pause

11:14 EDT Housing market has cooled as expected, Lennar says - Lennar says housing market has cooled as expected amid increasing interest rates but "has not stopped," and demand remains "strong." Production must catch up. Says it will conclude its spinoff plan by year-end. Comments taken from Q2 earnings conference call.

11:11 EDT Snap CEO calls paid subscription test 'an exciting opportunity' - Spiegel said the testing of Snapchat Plus, a new subscription service, is early, but he sees it as an "exciting opportunity." Snap CEO Evan Spiegel continues being interviewed by CNBC's Julia Boorstin from Cannes, France.

11:07 EDT Uber announces availability of UberX Share carpooling - In a company blog post, Andrew Macdonald, SVP of mobility and business operations at Uber, said, "Shared rides are arriving now! We're excited to announce that UberX Share is available in cities across the U.S., including New York City, Los Angeles, Chicago, San Francisco, Phoenix, San Diego, Portland, Indianapolis and Pittsburgh. We plan to expand UberX Share to even more cities this summer. Since pausing shared rides in 2020, our teams have been working tirelessly to revamp the experience. And after months of listening to driver and rider feedback, redesigning, testing, and troubleshooting through various pilots around the globe, the new UberX Share will allow riders to: Share a ride, get savings: riders will receive an upfront discount if they choose UberX Share, and get up to 20% off the total fare, if matched with a co-rider along the way. Stay on schedule: To prevent pickups and drop-offs from causing unexpected delays, we'll only match riders heading in the same direction. We've designed UberX Share so that riders arrive no more than 8 minutes later than an UberX ride. Make a sustainable choice: By helping to match more people in fewer cars faster, we can help cut gas use, vehicle-miles and emissions per passenger, and make transportation more affordable." Reference Link

10:51 EDT Anghami, MBC Group renew marketing agreement - MBC GROUP has set a new dimension for the marketing collaboration with Anghami and renewed its marketing agreement. This strategic partnership will feature Anghami across MBC GROUP's programming in the region, with a view to giving the platform access to airtime across various popular and key-market segment entertainment shows such as The Voice and Arab Idol, as well as MBC's TV channels, radio stations, its content streaming platform Shahid - the world's leading Arabic streaming platform - and all major social channels.

10:47 EDT Blackbaud appoints Chris Singh as CCO - Blackbaud appointed Chris Singh as Chief Customer Officer. Singh is the first leader to hold the newly created position at Blackbaud. Singh first joined Blackbaud in May 2021 as senior vice president of Customer Success. In his new role, Singh will oversee strategy and execution of the customer experience across Blackbaud under a shared vision to deliver at every stage of the customer life cycle.

10:33 EDT MyMD says all sites for Phase 2 clinical trial of MYMD-1 now enrolling patients - MyMD Pharmaceuticals announced further advancement in its fully-funded, multi-center Phase 2 clinical trial of lead drug candidate MYMD-1 as a therapy for delaying aging and expanding healthy lifespan. All clinical trial sites, including a world leading academic institution, are now enrolling patients. The Phase 2 multi-center double-blind, placebo controlled, randomized studyinvestigates the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of participants aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. In the Phase 1 dose-ranging study of MYMD-1 for delaying aging, subjects were treated with MYMD-1 or placebo and TNF-alpha levels were measured pre- and post-treatment. The data demonstrated a statistically significant decrease in TNF-alpha levels found in MYMD-1 treated subjects, but no change in the participants given placebo. This data was consistent with outcomes from pre-clinical models pointing to the drug's potential role in reducing both frailty and inflammatory cytokines.

10:25 EDT GeoPark provides business activity update - GeoPark provided an operations and business activity update. Accelerating Production Growth: Consolidated oil and gas production of 38,726 boepd; Production in Colombia of 34,234 boepd; CPO-5 block- gross production of 20,148 boepd due to the successful drilling and testing of the Indico 4 and Indico 5 development wells. Llanos Basin: In the CPO-5 block: The operator spudded the Urraca 1 exploration well on April 21, 2022, located 17 km northeast of the Indico field and 8 km southwest of the Llanos 34 block. In the Llanos 87 block: Obtained environmental license, allowing exploration and delineation drilling plus related infrastructure. Pre-drilling activities currently underway to spud the Tororoi exploration prospect in 3Q2022, to be followed by 1-2 exploration wells in 4Q2022. In the Llanos 34 block: Adding a third drilling rig, expected to start spudding wells in August 2022 Oriente Basin: Third Drilling Success in 2022. In the Perico block: On May 15, 2022, the operator spudded the Yin 1 exploration well, located to the southwest of the Jandaya oil field that was discovered in January. The well was drilled and completed to a total depth of 11,345 feet. Preliminary logging information indicated hydrocarbons in the Hollin formation. Preliminary production tests in the Hollin formation are currently showing a production rate of 1,600 bopd by natural flow of 27 degrees API with a 2% water cut. In the Espejo block: Completed the acquisition of 60 sq km of 3D seismic; Pre-drilling activities underway to spud the Pashuri 1 exploration well in September 2022; Putumayo Basin: Spudding New Attractive Short-Cycle Prospects. In the Platanillo block: Pre-drilling activities underway to spud the Alea NW 1 exploration well in late June 2022, to be followed by the Platanillo Norte 1 exploration well in 3Q2022. Production and operations affected for 15 days in May 2022 due to local community blockades with production fully restored to approximately 2,400 bopd. Llanos 34 interconnection to Colombia's national power grid expected to be fully operational by July 2022. Tua and Jacana fields interconnected in May/June 2022. Tigana field to be interconnected in July 2022. The interconnection of Llanos 34 to Colombia's national power grid is a decisive catalyst to reduce carbon emissions and improve overall operational reliability.

10:09 EDT DaVita trading resumes

10:07 EDT Capital Bank launches ZRent in partnership with ZSuite Technologies - Capital Bank announced the addition of ZRent to its portfolio of solutions in partnership with ZSuite Technologies, Inc. ZRent is a digital platform created by ZSuite Technologies. A responsive web app that automates the collection of rent and other monthly fees, ZRent simplifies the process for landlords, property managers and occupants/renters.

10:04 EDT DaVita trading halted, volatility trading pause

10:02 EDT Insight Enterprises partners with Vivli on AMR Register - Insight Enterprises announced that it has worked with Vivli to support the launch of Vivli's Antimicrobial Resistance Register. The global platform allows biopharmaceutical companies to share susceptibility data on infection-causing pathogens.

10:00 EDT Bancolombia falls -8.6% - Bancolombia is down -8.6%, or -$3.24 to $34.26.

10:00 EDT Ecopetrol falls -11.8% - Ecopetrol is down -11.8%, or -$1.62 to $12.06.

10:00 EDT PermRock Royalty Trust rises 15.1% - PermRock Royalty Trust is up 15.1%, or $1.07 to $8.11.

09:54 EDT TEGNA shareholders reelect board members, approve Say on Pay proposal - Shareholders of TEGNA approved the re-election of Board members, ratified the appointment of PricewaterhouseCoopers and approved an advisory resolution on the compensation of the company's named executive officers. Shareholders also voted in favor of a shareholder proposal to amend appropriate company governing documents to give the owners of a combined 10% of TEGNA's outstanding common stock the power to call a special shareholder meeting. TEGNA shareholders re-elected Board Chairman Howard Elias, president and CEO Dave Lougee, Gina Bianchini, Stuart Epstein, Lidia Fonseca, Scott McCune, Henry McGee, Bruce Nolop, Neal Shapiro and Melinda Witmer to the Board of Directors at the company's annual meeting held this morning. Directors will serve one-year terms ending at TEGNA's 2023 Annual Meeting of Shareholders. Susan Ness retired from TEGNA's Board of Directors effective today after serving for nearly 11 years. TEGNA's shareholders also ratified the appointment of PricewaterhouseCoopers as the company's independent registered accounting firm for the 2022 fiscal year and approved an advisory resolution on the compensation of the company's named executive officers reported in the company's 2022 proxy statement.

09:48 EDT Applied Minerals receives order for DRAGONITE halloysite clay - Applied Minerals has received an initial purchase order for 2,200 lbs. of its DRAGONITE halloysite clay for use in a corrosion-resistant coating formulation for metal products.

09:47 EDT Ecopetrol falls -7.7% - Ecopetrol is down -7.7%, or -$1.06 to $12.62.

09:47 EDT KE Holdings rises 10.3% - KE Holdings is up 10.3%, or $1.64 to $17.52.

09:47 EDT Convey Health rises 138.5% - Convey Health is up 138.5%, or $5.99 to $10.30.

09:35 EDT BetMGM, Sony Pictures Television, IGT to launch online Wheel of Fortune casino - BetMGM (MGM/GMVHF) announced an agreement with Sony Pictures Television (SONY) and International Game Technology (IGT) to launch Wheel of Fortune Casino, set to become the first full brand-led online casino in North America. Wheel of Fortune is preparing for its milestone 40th season. More than 250 versions of Wheel of Fortune slot games have been introduced over the last 25 years and this online launch of Wheel of Fortune Casino will represent the latest gaming extension for the brand. Launching first in New Jersey, Wheel of Fortune Casino will house America's Game-branded slot titles produced by global gaming leader IGT, along with many other themed games and features.

09:31 EDT Performance Shipping to acquire Aframax tanker for $27.58M - Performance Shipping announced that it has signed, through a separate wholly-owned subsidiary, a Memorandum of Agreement to purchase a 105,071 dwt Aframax tanker, the M/T Maran Sagitta, to be renamed M/T P. Sophia, built in 2009 by Hyundai Heavy Industries Co., Ltd. - Ulsan, South Korea, from an unaffiliated third party for a gross purchase price of US$27,577,320. The vessel, which is expected to be delivered to the Company on or about July 5, 2022, is fitted with a ballast water treatment system and its next scheduled special survey and drydock is not due until 2024. The Company expects to finance the acquisition cost with cash-on-hand raised from its recent equity offering and the incurrence of debt through a new senior secured facility that it anticipates it will enter into prior to delivery of the vessel.

09:30 EDT American Battery Metals announces results from drilling at Tonopah Flats - American Battery Technology Company announced drill results from its initial exploratory subsurface drill program, Phase 1, at its Tonopah Flats Lithium Project in Big Smoky Valley, Nev. This initial exploratory drilling program consisted of 16 targeted drill holes on ABTC's 10,340 acres of lithium-bearing claims, and was guided by surface sampling results collected in early 2022. ABTC drilled approximately 7,895-feet in this Phase 1 program and based on these results the company intends to further expand these exploration efforts to continue to advance this project. ABTC has developed its own proprietary processing train for extracting lithium from this type of unique Nevada-based lithium-bearing sedimentary claystone resource and for the subsequent manufacturing of this extracted lithium to battery grade lithium hydroxide for sale to the domestic battery supply chain. Whereas many proposed extraction processes are only able to produce economically competitive lithium products from high lithium grade material, the low-cost and low-environmental impact manufacturing process that ABTC has developed is able to produce battery grade lithium hydroxide from a wide variety of lithium concentrations hosted within these sedimentary resources. ABTC, in collaboration with DuPont, was recently awarded a $4.5M grant from the US Department of Energy to build and operate a multi-ton per day demonstration-scale system to accelerate the commercialization and scale-up of this critical lithium manufacturing technology. Highlights from this Phase 1 drilling program include: Shallow Overburden: Anomalous lithium concentrations were measured at very shallow depths, less than 50 ft below the surface in many cases, indicating that low-cost and low-strip ratio techniques can likely be applied to access these near-surface lithium-bearing sedimentary materials. Consistent Lithium Concentrations: Lithium concentrations above the reference cutoff concentration of 300 ppmw were observed in every drill hole, in consistent concentrations throughout a large percentage of the total sampled depths, and with significantly higher peak concentrations observed in many sample holes, which makes this deposit especially attractive to the internally-developed ABTC processing train. Depth of Mineralization: The drilling infrastructure employed in these explorations was able to drill to a depth of approximately 500-ft, and in several of these drill holes the significant mineralization of lithium is still present at these depths, indicating that the anomalous lithium presence could extend even beyond the sampled depths. Breadth of Exploration: With these initial 16 drill holes a wide breadth of ABTC claims have been explored, and when considering a 0.5-mile radius area of influence around each drill hole, approximately 4,990 acres out of 10.320 acres of total claim area has been explored within this Phase 1 program. Magnitude of Deposit: With the anomalous lithium concentrations observed throughout the detailed exploratory drill holes, and throughout the listed sampling depths, the ABTC team is excited to accelerate the further exploration and characterization of these claims to advance this deposit to an inferred, indicated, and measured resource through the established S-K 1300 guidelines. Next Steps: ABTC will utilize the results from this Phase 1 program to develop a step-out drill program, Phase 2, to further characterize the deposit. Additional drill results on Phase 2 will aid in the determination of area-wide grade and thickness assessment of the in-situ amount of lithium in order to progress this deposit to a quantified resource.

09:27 EDT HUB Cyber Security advances merger with Mount Rainier Acquisition - HUB Cyber Security, a developer of Confidential Computing cybersecurity solutions and services, announced that the expected merger with Mount Rainier Acquisition (RNER) advances as planned, and as further measures to secure the merger at the shareholders vote meeting, company executives and board have decided to waive their right to shares incentives guaranteed to them as part of the merger agreement. Such share incentives may deem the executives as unqualified for voting by the Israeli law and therefore potentially jeopardize the vote entirely on the merger deal. By unilaterally waiving the rights for the share incentives, the company has de-facto secured the vote of all qualified shareholders in the upcoming shareholders meeting to approve the SPAC merger deal.

09:23 EDT Exela Technologies closes $150M securitization facility with PNC Bank - Exela Technologies reported the closing of a three-year $150 million financing facility with PNC Bank. The new facility replaces the Company's existing securitization facility and is expected to provide annual interest savings of $6 million based on current borrowing levels priced at L+400 bps

09:21 EDT Surna secures LOI with Greene Brothers Farms to supply products, services - CEA Industries subsidiary, Surna Cultivation, announced it has entered into a letter of intent to provide products and mechanical engineering services over five phases with Greene Brothers Farm, Inc., a family owned and operated farm that is developing a 26-acre site exclusively for indoor cannabis cultivation. CEA Industries anticipates contract revenues of approximately $10 million over an estimated two to three-year period. The initial contract, valued at $1.2 million, is for the first phase of products and services and is planned to be completed by early Q4 2022. The project builds out a new all-indoor Cannabis Park, located in Lockeford, California, between Stockton and Sacramento, on a 26-acre property once used as a vineyard and wine distribution center. The Greene Brothers Farm Cannabis Park is an ambitious major expansion of the Greene Brothers' operations that are currently located at a 200-acre farm in Mendocino County. The Cannabis Park will be the new headquarters for the Greene Brothers and will include cultivation, manufacturing, non-storefront retail sales and distribution. Once complete, the Cannabis Park will utilize 371,918 square feet of new structures. Phase 1 is estimated to be online by Q4 of this year. For this first phase, Surna will perform mechanical engineering services that will include the design of exhaust air filtration systems to eliminate odors as well as to provide climate controls systems, its EnviroPro air handling equipment and Surna by Anden dehumidifiers. Phases 2 and 3 are planned for completion in 2023, while phases 4 and 5 are planned for completion in 2024.

09:18 EDT Terreno Realty acquires $19.9M industrial property in Washington - Terreno Realty acquired an industrial property in Redmond, Washington for a purchase price of approximately $19.9M. The 3.5-acre improved land parcel at 8660 Willows Road is between I-405 and SR 520 and less than one-half mile from Terreno Realty's properties at 9045 Willows Road and 14505-14515 NE 91st Street. The property is 38% leased to one tenant and the estimated stabilized cap rate is 4.3%.

09:17 EDT Kroger adds new customer fulfillment center in Aurora, Colorado - Kroger announced it will offer more Americans delivery through the addition of a new customer fulfillment center in Aurora, Colorado, powered by the Ocado Group, engineering a model for the region, leveraging advanced robotics technology and creative solutions to redefine the customer experience in the Denver Metro Area. The nearly 300,000 square-foot distribution center will bring nearly 400 new jobs to Aurora and adjacent communities.

09:15 EDT Focus Universal set to join Russell 2000 Index - Focus Universal is set to join the broad-market Russell 2000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, according to a preliminary list of additions posted June 3.

09:15 EDT RADA Electronic trading resumes

09:12 EDT Pfizer, Truveta enter strategic collaboration for safety insights - Truveta announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world data at scale. Truveta will provide Pfizer with an unprecedented data platform for research. The data collected by Truveta are always flowing, providing the most up-to-date picture of U.S. health. Pfizer will use de-identified data from Truveta to identify, monitor, and evaluate potential signals in near-real time, informing efforts to mitigate risks and enabling further research.

09:09 EDT Vicarious Surgical to join Russell 3000 Index - Vicarious Surgical announced it is set to join the broad-market Russell 3000 Index as well as the Russell 2000 and Russell Microcap Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on June 3. Inclusion in the index will take effect after the U.S. market opens on June 27.

09:08 EDT Verizon announces $200M invested in network in North Carolina in 2021 - In 2021, Verizon invested over $200M in its network in North Carolina. That investment expanded capacity on the company's 4G LTE network and introduced 5G service to nearly 2.5M customers throughout the state, and North Carolinians are loving the new service. There has been a 215% increase in 5G data usage in NC since January of 2022. During 2021, the Verizon Frontline Response Team deployed more than 30 times in support of public safety agencies in North Carolina to provide mission-critical communications capabilities to the first responders on the front lines of multiple emergency response operations. During 2021, the Verizon Frontline Response Team provided support to North Carolina public safety agencies during Winter storms, hurricanes, wildfires, flooding events and supported first responders in North Carolina's Wake County during a mass COVID-19 vaccination effort at PNC Arena. In 2021, Verizon invested over $5,000,000 in charitable contributions and programs in the state.

09:07 EDT CBAK Energy Technology to develop cylindrical batteries for Jemmell - CBAK Energy's wholly owned subsidiary Nanjing CBAK has entered into a strategic framework agreement with Jiangsu JPK New Energy, a subsidiary of Jiangsu Jemmell, to develop and supply large cylindrical batteries used on Jemmell's A00-grade mini passenger vehicles. Nanjing CBAK and JPK will cooperate to develop a competitive EV power battery system. Specifically, Nanjing CBAK will be responsible for providing batteries with an EV-used battery solution that allows its products to be applicable under several scenarios. This agreement is expected to generate tens of millions of revenues in RMB to the company, subject to the actual number of batteries supplied.

09:06 EDT USPI and United Urology Group to form joint venture - United Surgical Partners International , a subsidiary of Tenet Healthcare and United Urology Group one of the nation's largest networks of urology affiliate practices, today signed a definitive agreement to form a joint venture partnership in 22 ambulatory surgery centers . USPI will acquire a portion of UUG's ownership interests in well-established and brand-new facilities located in Maryland, Colorado and Arizona. A partnership with USPI will help UUG and its affiliated practices accelerate the delivery of ASCs in new markets and make patient care more accessible. The addition of UUG and its affiliated practice ASCs will complement USPI's growing urology service line and expand its partnership network with more than 140 leading urology physicians. "United Urology Group's premier affiliated practices have set a very high standard for exemplary urologic care," said Brett Brodnax, President and CEO of USPI. "The partnership will add high-quality urology centers within our existing markets. We are honored to serve additional patients and support the growth of these ASCs." "USPI's commitment to innovation and depth of operational knowledge will benefit the growth and development of our ASCs," said Sanford J. Siegel, MD, CEO of United Urology Group. "We have an exciting runway with USPI as our partner and look forward to bringing our patient-focused cultures together." The transaction is expected to be completed in the third quarter, subject to regulatory approvals and closing conditions. Upon completion, USPI will manage and jointly own the centers with UUG and its affiliated practices. The centers will be consolidated in Tenet Healthcare's financial statements.

09:05 EDT Clearmind appoints John Krystal to Scientific Advisory Board - Clearmind Medicine announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University's School of Medicine. A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystal's work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine.

09:04 EDT El Pollo Loco announces 'Abuela Approved' campaign - El Pollo Loco announced am "Abuela Approved" campaign, featuring a newly appointed 'Head Abuela in Charge,' here to authenticate the restaurant's cuisine and bring sass and laughs to TikTok. Through a series of videos directed by Yubicela Brito, El Pollo Loco's Abuela will act as chief authenticator, giving her sassy, comedic commentary and stamp of approval, or disapproval, on everything from buzzworthy pop culture moments, hot TikTok trends and of course, El Pollo Loco's lineup of mouthwatering L.A. Mex cuisine that gives Abuela's home cooking a run for her money. The content series kicked off today with Abuela's TikTok debut and will continue to rollout on the platform throughout the summer.

09:03 EDT NetSol Technologies signs agreement with Yamaha Motor Finance - NetSol Technologies (NTWK) has signed a contract with Yamaha Motor (YAMHF) Finance Canada for a further implementation of NETSOL's LeasePak solution. "It gives us great pleasure when existing clients continue to place their trust in us when expanding their operations in different countries or regions," said Najeeb Ghauri, Founder, Chairman and CEO of NetSol Technologies. "Yamaha is a bluechip company and is world-renowned. By signing an agreement with NETSOL to deploy our LeasePak platform in Canada, the client will be enabled with a superior, end-to-end portfolio management solution to ensure their operations are executed seamlessly and cost-effectively."

09:03 EDT Cincinnati Financial Chief Investment Officer Martin Hollenbeck to retire - Cincinnati Financial announced that Martin Hollenbeck, CFA, CPCU, chief investment officer, executive vice president, assistant secretary and assistant treasurer, provided notice on June 20, of his plan to retire on September 30. Steven Soloria, CFA, CPCU, vice president, Investments, will assume executive responsibility for the investment operations of Cincinnati Financial and its U.S.-based subsidiaries upon Hollenbeck's retirement. Soloria is a seasoned professional with nearly 30 years of experience in Cincinnati's investment department.

09:02 EDT Hookipa Pharma announces executive leadership changes - HOOKIPA Pharma announced several leadership changes as the company expands its clinical development and pipeline programs. All new appointments are effective July 1, 2022. After five years, Igor Matushansky will step down as Chief Medical Officer, CMO, and Global Head of Research & Development, effective June 30, 2022. Matushansky will continue to contribute to HOOKIPA's pipeline development as Chair of HOOKIPA's Scientific Advisory Board. Katia Schlienger has been promoted to Executive Vice President, Clinical Development. Schlienger was previously Senior Vice President, Head of Immuno-oncology. Roman Necina, Chief Technology Officer, is appointed to the newly created role of Chief Development Officer. In addition to his current manufacturing responsibilities, he will be responsible for integrating Portfolio and Project Management, IT & Knowledge Management, and Operational Excellence across all line functions, with the goal of the accelerating the pipeline.

08:59 EDT BIO-key showcases biometric cybersecurity solutions at MSP Expo Florida - BIO-key International will showcase its solutions in Booth #536 at MSP EXPO June 21-24, 2022 at the Broward County Convention Center, Fort Lauderdale, Florida. Produced by TMC, MSP EXPO is the premier conference and networking summit for Managed Service Providers, with expanded reach via its collocation with ITEXPO. BIO-key looks to both support and expand its growing base of Managed Service Providers and Managed Security Service Providers, highlighting the value and capabilities of its differentiated cybersecurity solutions and sharing strategies with channel partners on how to grow their businesses with BIO-key solutions.

08:56 EDT Gladstone Capital acquires California olive orchard for $24.5M - Gladstone Land announced that it has acquired 1,374 gross acres of farmland located in Glenn County, California, for $24.5 million from Solum Partners, headquartered in Boston, Massachusetts. In connection with the acquisition, Gladstone Land also entered into a 15-year, triple-net lease agreement with California Olive Ranch, reported to be the largest miller of olives for extra virgin olive oil in the U.S. and the producer of the nation's top-selling 100% California EVOO.

08:55 EDT Jabil teams with SolarEdge to advance smart energy technology - Jabil announced that it is teaming up with SolarEdge, a firm in smart energy technology, to help change how power is harvested and managed in photovoltaic systems. A shared focus on manufacturing excellence and automation has led to the installation of more than 2.5 million intelligent power inverters and more than 60 million power optimizers in over 130 countries across five continents...Rigorous quality requirements demand fastidious tracking of every production step to identify any potential reliability issues or possible product defects, which are critical factors when building products with extended warranties. "We've done tremendous things together to create an optimum manufacturing environment," said Scott Gebicke, Senior Vice President, Industrial Division, Jabil. "We deployed an automated solution that enables Jabil to operate in the leanest and most efficient way possible while decreasing manufacturing time by almost 50%. This makes a big difference when you're making tens of thousands of products each week, if not millions in a month."

08:54 EDT U.S. Gold provides update on CK Gold Project permitting process - U.S. Gold provided an update on the status of its preparations to file mine construction and operating permits for its CK Gold Project, within the next few months for consideration by the State of Wyoming authorities. The company believes it is unlikely that there would be any significant U.S. federal governmental involvement in the project's permit review and approval process. Studies assessing the impacts of the proposed project have been prepared and are being collated into the permit application, which are expect to be submitted in the coming months. The CK Gold Project, seeking to recover copper, gold and silver bearing minerals, will be an open pit mine utilizing similar equipment and techniques to the Granite Canyon quarry, 3 miles south. The project does not plan to employ a conventional tailings dam, will focus on the conservation of water, will not have a smelter or refinery on site, and will not use toxic chemicals often associated with gold extraction. The company's studies to date suggest that the CK Gold Project open pit could have the potential to double the current water storage without deleterious effects on the water. The company, at no cost to the community, plans to continue to study the possible use of the open pit as a water storage facility and to present the concept for consideration. To ensure that blast studies are correct, a local company drilled two shallow holes and set off some 300 pounds of explosives in each hole. The data is being used to confirm the findings that blasting can occur at the project without damage to property or infrastructure.

08:52 EDT ProFrac Holding to acquire West Texas units of Signal Peak Silica for $90M - ProFrac Holding announced that its subsidiary, ProFrac Holdings II, has entered into a definitive agreement to acquire SP Silica of Monahans and SP Silica Sales, the West Texas subsidiaries of Signal Peak Silica, for approximately $90M. No additional terms were disclosed. Matt Wilks, Executive Chairman, added, "The Monahans operation brings us a dedicated and dynamic workforce and, by the third quarter of 2022, would expand our total to three in-basin sand mines within the ProFrac portfolio. SPS Monahans provides nearly 3 million tons of annual sand production capacity of 40/70 and 100 mesh and includes nearly 25,000 tons of on-site storage. Once closed, this transaction brings our companywide annual sand production capacity to approximately 6 million tons, which is expected to increase to approximately 8 million tons when we complete our West Munger facility in the Permian, which is expected to occur by the third quarter of 2022."

08:47 EDT Mullen Automotive extends maturity of senior secured convertible note - Mullen Automotive announces that it has extended the maturity of a senior secured convertible note of $28 million, originally due in July 2022, by two years. The Company originally entered into a secured convertible promissory note on July 23, 2020, with DBI Lease Buyback Servicing LLC, an affiliate of Drawbridge Investments. Esousa Holdings, LLC, an existing Mullen shareholder, has acquired the Note from Drawbridge and entered into an agreement with Mullen to extend the maturity date of the Note by two years. The original Note was scheduled to mature on July 28, 2022, and the Note is now extended to July 2024.

08:47 EDT Anixa Biosciences' licensed ovarian cancer vaccine featured in publication - Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research. The article discusses pre-clinical studies of a preventative ovarian cancer technology that has been licensed to Anixa. This ovarian cancer vaccine targets the extracellular domain of anti-Mullerian hormone receptor 2 expressed in the majority of ovarian cancers. The journal article highlights study data demonstrating formulation of the AMHR2-ED vaccine with AddaVax adjuvant induced high serum titers of immunoglobulin G and significant inhibition and destruction of epithelial ovarian cancer with significantly enhanced overall survival of animals in both prevention and therapeutic protocols. Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute.

08:46 EDT Point Biopharma appoints Horvath as EVP, Commercial - POINT Biopharma Global announced the appointment of Chris Horvath, as Executive Vice President, EVP, Commercial. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or worked on the launch of a number of key oncology products. In his new role at POINT, Horvath will lead the commercial strategy for POINT's pipeline.

08:44 EDT Phunware releases PhunWallet Version 1.3 mobile app update - Phunware announced the release of PhunWallet version 1.3, an updated mobile application software on the Apple App Store and Google Play for Android. The latest app update enables users to log in and out across devices seamlessly, using the same username and password to easily access their accounts. It also offers users more opportunities to earn PhunToke,, the innovative cryptocurrency created by Phunware to reward consumers for their engagement in profitable behaviors, such as completing surveys or watching videos from specific brands.

08:43 EDT Lixte announces appointment of Bas van der Baan to board of directors - Lixte Biotechnology announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director.

08:42 EDT AIM ImmunoTech secures new facility for product development, testing - AIM ImmunoTech announced it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot R&D facility at the New Jersey Bioscience Center, NJBC. AIM Chief Executive Officer Thomas Equels commented, "The AIM team is pleased to join a number of thriving, prestigious life sciences companies at the NJBC. This state-of-the-art facility will help us to continue to advance our research and development of Ampligen to treat multiple types of cancers, immune disorders, and viral diseases. We have made a significant investment in new equipment for this facility and believe that this space will enhance our future development progress."

08:41 EDT Save Foods announces results of independent study of treatment on mangos - Save Foods announced results of an independent study that shows Save Foods' treatment can extend the shelf life and freshness of mangos while virtually eliminating the use of post-harvest pesticides. Approximately 26% of mangos are lost between harvest and consumption. Pesticides are commonly applied in the post-harvest stage in order to reduce the loss of produce to decay. Growing concerns about the toxicity of chemical pesticides as well as increasingly stringent regulations regarding their use, especially in Europe, appear to indicate why there is an increase in the adoption of Save Foods' eco crop protection treatments. With the recent organic recognition of one of Save Foods' products, consumers can enjoy long-lasting pesticide-free mangos.

08:41 EDT Blue Star Foods selects HTH Engineering to build expanded Soft-Shell crab RAS - Blue Star Foods announced that it has selected HTH Engineering & Equipment as its the Recirculating Aquaculture Systems, RAS, technology provider for its planned expanded Soft-Shell Atlantic Crab RAS farm in Jasper County, South Carolina. Blue Star has signed a multi-phase engineering contract with HTH to provide planning, design and consulting services to create a new facility that, when fully built, will be able to harvest over 220,000 dozen a year of Soft-Shell Atlantic Blue Crab. The new operation will be in Jasper County, South Carolina. This new location will replace the existing operational footprint that is currently in Beaufort County, South Carolina. "We launched the Soft-Shell Crab RAS business division in March 2022, and we are very pleased with the speed and cost at which we were able to launch and come to market. The immediate expansion of the Crab RAS business was one of the major drivers for profitable growth, and we are excited to work with HTH on this expansion," said John Keeler, Chairman and CEO of Blue Star.

08:40 EDT Marsh McLennan names John Jones as Chief Marketing and Communications Officer - Marsh McLennan announced the appointment of John Jones as Chief Marketing and Communications Officer and Pat Hagemann as Office of the COO Chief of Staff. Mr. Jones and Ms. Hagemann will report to John Doyle, Group President and Chief Operating Officer of Marsh McLennan. The appointments are effective July 1. "I have deep respect for the expertise and professionalism that John and Pat bring to their new roles," said Mr. Doyle. "Their appointments will help us deliver our enterprise strategy to drive greater client impact and to be more agile and collaborative." Jones will lead Marsh McLennan's new marketing and communications organization, which will support the Company's four businesses, Marsh, Guy Carpenter, Mercer and Oliver Wyman, and the Marsh McLennan Advantage group, which drives cross-business initiatives, partnerships and thought leadership.

08:39 EDT Lincoln National appoints Amber Williams as chief sustainability officer - Lincoln Financial has appointed Amber Williams, senior vice president and head of client investment strategies, to lead corporate sustainability as the chief sustainability officer, Lincoln announced. Williams' elevated responsibilities come as the investments and risk organization welcomes sustainability within its purview - a move that aligns Lincoln's structure with its long-term strategic business plan being driven by newly appointed CEO Ellen Cooper.

08:38 EDT Franchise Group announces sale of W.S. Badcock corporation distribution centers - Franchise Group (FRG) announced that it has completed the sale-leaseback of all three W.S. Badcock Corporation distribution centers for gross proceeds of approximately $150M to affiliates of Oak Street Real Estate Capital, a division of Blue Owl Capital (OWL). "Oak Street has proven to be a trustworthy partner throughout our sale leaseback process," said Brian Kahn, President and CEO of Franchise Group. "We are pleased to close the sale of the Badcock distribution centers and retire the balance of our acquisition term loan with the cash proceeds."

08:36 EDT Rigetti Computing launches Aspen-series quantum computer in the UK - Rigetti UK Limited announced the launch of its 32-qubit Aspen-series quantum computer in the UK. The system, which is Rigetti's first UK-based quantum computer, will be available to its UK partners over the cloud through Rigetti QCS.

08:34 EDT Digital Brands revises terms of Sundry acquisition - Digital Brands and Sunnyside - Sundry - revised their definitive acquisition agreement to require less cash and equity to close the transaction. Under the terms of the revised agreement, holders of Sundry membership interests will exchange all such interests for $5.0M in cash, $7.0M paid in either cash or equity, at the option of the sellers at the issuance price, and $20.0M in equity valued at the Issuance Price. The company has received several options for debt financing to cover the capital cost of the acquisition. Company stockholder approval will be required to close the transaction. The company believes the transaction should close in Q3. The acquisition is expected to be accretive to EBITDA immediately upon completion. Sundry generated $22.8M in revenue in 2021 versus $19.9M in 2020, a 14.5% increase year-over-year. The company believes the acquisition should create meaningful synergies between all its portfolio brands, significantly lowering customer acquisition costs and increasing customer retention, annual spend per customer and lifetime value per customer. Sundry is an omnichannel women's lifestyle apparel brand.

08:34 EDT Acer Therapeutics, Relief announce update on FDA review of NDA for ACER-001 - Acer Therapeutics (ACER) and its collaboration partner, Relief Therapeutics (RLFTF), announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, regarding the New Drug Application, NDA, for ACER-001 for oral suspension for the treatment of patients with urea cycle disorders. The CRL indicates that the FDA cannot approve the NDA in its current form. The FDA did not cite any other approvability issues in the CRL pertaining to the NDA, nor request any additional clinical or pharmacokinetic studies be conducted prior to FDA approval. The FDA did provide one comment in the CRL requesting additional existing nonclinical information to be provided in the resubmission of the NDA. "While the outcome of the NDA review was not what we had hoped for, multiple rounds of labeling negotiations have already been conducted to date and we believe the recommendations raised by FDA can be appropriately addressed. We should be able to resubmit the NDA relatively quickly," said Chris Schelling, CEO and Founder of Acer. "We remain committed to bringing a new treatment option to patients in the U.S. with UCDs."

08:34 EDT Lightwave Logic announces publication of a U.S. patent application - Lightwave Logic announced the publication of a U.S. patent application on a new invention that will enhance polymer modulator manufacturing in high-volume foundries when integrated with silicon photonics. This patent application - entitled "Hybrid electro-optic polymer modulator with silicon photonics" under publication number 2022/0187637A1 - details a novel fabrication process that allows Lightwave Logic's proprietary polymers to be fabricated by silicon foundries in a high-volume manufacturing environment. The published patent application also details a more efficient process that allows for high yielding, high stability poling of polymers in a high-volume foundry manufacturing environment. The development of the PDK for this new optical hybrid optical modulator design is now in progress with Lightwave Logic's foundry partners.

08:30 EDT 9 Meters Biopharma trading resumes

08:28 EDT Ferguson announces transaction in own shares - Ferguson plc announces that on June 20, 2022 it purchased for Treasury the following number of its ordinary shares of 10 pence each in connection with its $2 billion share repurchase program. Number of shares repurchased: 158,000. The Company intends to hold these Shares in Treasury. Including Shares which have been purchased but not yet settled, the Company holds 19,581,176 Shares in Treasury. Following the purchase of these shares, the remaining number of ordinary shares in issue will be 212,590,006.

08:25 EDT OverActive Media announces changes to MAD Lions leadership team - OverActive Media announced changes to the MAD Lions leadership team in Madrid, Spain. Jorge Schnura, Vice-President of Strategy, is resigning from his current role to pursue a new business venture and will continue in an advisory capacity with the Company. Ricardo Gomez-Acebo Botin, Director of Business Operations has been promoted to Head, EU Business with oversight of the Partnerships, Marketing and Business Operations functions in Europe. Gomez-Acebo Botin has worked with Schnura for the past four years, helping lead the sale of MAD Lions to OverActive Media in 2019. The OverActive team will work closely with Schnura to ensure the MAD Lions leadership team is well positioned for continued success in the future. Schnura's last day at OverActive will be July 29, 2022.

08:24 EDT IsoRay announces two presentations on Celsium-131 - Isoray announces two presentations on Cesium-131 in treating prostate cancer at the American Brachytherapy Society's annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory Group. One of the presentations was entitled, Permanent LDR brachytherapy using Cesium-131 Monotherapy: Updated Recommendations from the Cesium Advisory Group. The authors noted that Cesium-131 has a higher photon energy as well as a shorter half-life in comparison to its counterparts, Iodine-125 and Palladium-103. They stated that the optimal Cesium-131 implant will deliver a safe and effective dose with the minimum possible toxicity. A review of implant techniques examining variability and/or similarity of different sized prostates for each brachytherapist was undertaken. The data acquired was compared to the past Cesium Advisory Group's 2008 recommendations. The Cesium Advisory Group's second presentation was entitled, Technique and Preferences for Permanent LDR Prostate Brachytherapy Using Cesium-131. The purpose of their study was to identify individual technique preferences for Cesium-131 prostate implantation and determine if there is a uniform method among the brachytherapists. While Cesium-131 implants vary on several specifics with regards to technique, the brachytherapists on the panel are uniform in their practice to implant the majority of the Cesium-131 isotope in the periphery. This so-called "peripheral loading" takes dose away from the urethra where it might cause unwanted urinary symptoms. No matter how the Cesium-131 implant is planned and administered, homogeneity and sparing of the nearby sensitive anatomy is recommended and achievable.

08:22 EDT Gevo, Finnair enter SAF sales agreement for 7M gallons - Gevo (GEVO) announces a new fuel sales agreement with Finnair (FNNNF). The Agreement outlines the details for the purchase of 7M gallons per year of sustainable aviation fuel, SAF, for five years from Gevo's commercial operations. Deliveries of the SAF by Gevo are expected to begin in 2027. The expected value for the Agreement to be $192M over the five-year period, inclusive of the value from environmental benefits for Gevo. The Agreement with Finnair will broaden Gevo's range of airline partners and grow its global footprint with its sustainable fuel products, and also supports our efforts in pursuit of our stated goal of producing and commercializing a billion gallons of SAF by 2030. "Gevo was founded on the principle of building sustainability into every step of our process," said Dr. Patrick Gruber, Gevo's Chief Executive Officer. "But it is not static-it's always improving: We're constantly incorporating new developments at every stage of our business system to reduce our carbon intensity. This is expected to make the renewable energy carried in our advanced renewable fuels even more impactful as they help to lower our customers' carbon scores."

08:20 EDT Olink announces publication of proteomics research conducted by UKB-PPP - Olink Holding announced that a publication describing the early findings of proteomics research conducted by the UK Biobank Pharma Proteomics Project was published online to the bioRxiv preprint server. The study, titled "Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants," utilized Olink(R) Explore 1536 and genome sequencing on 54,306 UK Biobank participants to gather and analyze data from protein quantitative trait loci mapping of 1,463 proteins identifying 10,248 primary genetic associations, of which 85% have not been previously reported. The results from the UKB-PPP publication provide an updated genetic atlas of the plasma proteome and provide the scientific community with an open-access, population-scale proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries. Measuring thousands of proteins at population scale has promise to improve our understanding of underlying mechanisms of disease, and therefore accelerate the development of novel biomarkers and therapeutics. Furthermore, the study highlights the strengths of Olink's Explore assay for pQTL detection and downstream biological discovery, with a high proportion, 82% of the proteins tested, having cis associations, evidence of Olink's highly specific assays that measure their intended proteins. The UK Biobank Pharma Proteomics Project is a collaboration between UK Biobank and thirteen biopharmaceutical companies, and is currently performing one of the world's largest scientific studies of blood protein biomarkers. The UK Biobank is a large-scale, biomedical database and research resource containing in-depth genetic and health information from half a million UK participants. The database is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UKB-PPP aims to enable better understanding of disease biology and support innovative drug development for more effective therapies.

08:19 EDT Quanergy receives NYSE non-compliance letter regarding stock trading price - Quanergy Systems announced that it received notice on June 17, from the New York Stock Exchange that the price of its common stock fell below the NYSE's continued listing standards. The NYSE requires the average closing price of a listed company's common stock to remain above $1.00 per share over a consecutive 30 trading-day period. As of June 16 the 30 trading-day period average closing price of the Company's common stock was 85c per share. The Company has six months to regain compliance with the NYSE continued listing requirements. During the six-month period, the Company's common stock will continue to be listed and traded on the NYSE, subject to compliance with other continued listing standards. The deficiency does not affect the Company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements. To address this issue, Quanergy intends to monitor the trading price of its listed securities and take steps to increase the value of its shares through implementation of its business strategy, and is considering other options for regaining compliance with the NYSE's continued listing standards.

08:18 EDT BigCommerce renews partnership with Klaviyo - Klaviyo announced it renewed its partnership with BigCommerce as an Elite Technology Partner, continuing the company's history of closely partnering with platforms to help brands achieve revenue growth through ecommerce.

08:18 EDT TuSimple CFO Patrick Dillon stepping down - TuSimple CFO Patrick Dillon will leave the company to pursue other opportunities. Eric Tapia, Global Controller and principal accounting officer, will temporarily take on the role of the company's CFO while TuSimple carries out a search for a new CFO. The company is also promoting Ersin Yumer to Executive VP of Operations and Lei Wang to Executive VP of Technology.

08:17 EDT Microchip announces AVR-IoT Cellular Mini Development Board - Microchip Technology announces the AVR-IoT Cellular Mini Development Board based on the AVR128DB48 8-bit microcontroller.This solution provides a robust platform to start building sensor and actuator nodes on 5G narrowband IoT networks. The AVR-IoT Cellular Mini Development Board is a small form factor board, making it an ideal solution for developers who want to connect IoT devices to an available 5G network. This is an essential feature for devices on the go or located in remote areas with limited availability of Long Range networks or other Low Power Wide Area Network solutions. Customers can tap into the flexibility and ease of design offered in the latest AVR128DB48 8-bit MCU family, including security protection with Microchip's ATECC608 CryptoAuthentication device. The ATECC608 device can easily be configured to most major cloud service providers through Microchip's IoT Provisioning Tool.

08:16 EDT Nuvectis Pharma receives FDA clearance for NXP800 IND - Nuvectis Pharma announced that the U.S. Food and Drug Administration cleared the Company's Investigational New Drug Application for NXP800, which includes the Phase 1 clinical trial protocol. The NXP800 Phase 1 clinical trial is comprised of two parts, a dose escalation study to be followed by an expansion study. The Phase 1a is currently ongoing in the United Kingdom and, with the IND in effect, U.S. clinical sites will now be included. The Company expects to initiate the Phase 1b study in early 2023.

08:14 EDT Anavex announces educational video news release - Anavex Life Sciences announces Anavex's very first Educational Video News Release, which can be accessed via Anavex's newsroom.

08:13 EDT Wireless Telecom's Noisecom introduces 60 GHz jitter noise generator - Wireless Telecom Group announced that its Noisecom brand has introduced a new, 60 GHz jitter noise generator, setting a new benchmark for high frequency noise generation in a programmable instrument. Along with the introduction of this record-setting performance, the full line of Noisecom J7000B jitter noise generators from 10 MHz to 60 GHz are now being built using the innovative UFX7000B platform and streamlined user interface. The J7000B jitter noise generator is the ideal tool for introducing random jitter into a serial data bus to test for system robustness and compliance with industry standards for current, emerging, and next-generation protocols. Available in several off-the-shelf models, but highly customizable, the J7000B can be configured to meet the unique testing requirements of new systems and chipsets even in the earliest stages of development and test.

08:13 EDT APA Corp. announces flow test results at Krabdagu discovery well - APA Corporation (APA) announced flow test results from the Krabdagu exploration well, KBD-1, on Block 58 offshore Suriname. APA Suriname holds a 50% working interest in the block, with TotalEnergies (TTE), the operator, also holding a 50% working interest. Flow test data collected in the two lower intervals, the Upper Campanian and Lower Campanian, indicates oil-in-place resource of approximately 100 and 80 million barrels respectively connected to the KBD-1 well. These tests were performed in the exploration well, and appraisal drilling will be necessary to confirm additional resource and optimal development well locations. "The results from the Krabdagu flow-test in the two lower intervals are in line with our expectations and provide data that accelerates our understanding of the field and will shape future activity. This includes identifying the optimal well locations that enable assessment of upside resource potential for each target," said John Christmann IV, APA's CEO and president. "The connected resource demonstrated from the flow tests at Krabdagu combined with the results from Sapakara South, are a significant step forward in advancing a project in this area of Block 58."

08:11 EDT Cabildo de Tenerife deploys Infinera's XTM Series - Infinera announced Cabildo de Tenerife has deployed Infinera's XTM Series across its regional government network infrastructure to increase broadband connectivity throughout the island. Utilizing Infinera's XTM packet-optical solution, government departments throughout Tenerife will be able to enjoy flexible optical and high-speed internet services and extended site connectivity, enabling interconnection of almost all government facilities around the island via the government's corporate data processing center located in the D-ALiX data center facilities.

08:10 EDT Healthcare Triangle authorizes $2M share repurchase program - Healthcare Triangle announced that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2M of its common stock. "The authorization of this share repurchase program reflects our management's confidence in the potential of the organization and our ability to generate long-term shareholder value," said Suresh Venkatachari, Chairman and Chief Executive Officer. "With the growth momentum in our cloud based platform and managed services business, we believe we are poised for a strong 2022 in our healthcare and life sciences businesses as we look to expand our footprint across North America and the international markets. We strongly believe there is a disconnect between our current share price and the intrinsic value of our common stock, based on what we believe to be Healthcare Triangle's future earnings potential."

08:09 EDT Otonomo Technologies says Electric Zoo using Smart Mobility Data Platform - Otonomo Technologies announced that Electric Zoo, a pay-as- you-go electric car subscription service, is using Otonomo's GDPR-compliant Smart Mobility Data Platform to easily manage and track its fleet of electric vehicles. With access to accurate mileage data, Electric Zoo is able to improve operations and explore new business opportunities and subscription models, including implementing flex-pay options and offering low mileage discounts. Using Otonomo's near real-time GPS data, Electric Zoo can track the location of their vehicles, how many miles each vehicle is being driven, and the distances traveled by individual vehicles or by fleet.

08:09 EDT CLPS partners with Educare Global Academy for fintech education in Singapore - CLPS, through its wholly-owned subsidiary CLPS Technology Singapore, has signed a Collaboration Agreement with Educare Global Academy, a private educational institution in Singapore. Under the Agreement, CLPS and Educare Global Academy will collaborate and integrate their respective industry expertise and resources to provide an education program focused on banking and fintech, the Post Graduate Diploma in New Banking Technologies: Application, Implementation & Legacy Systems Integration. The education program is open to anyone with a bachelor's degree in information technology, computer science, engineering, banking and finance, or an equivalent discipline along with relevant work experience. CLPS will provide students with internship interview assistance and mentoring, as well as arranging job interviews for successful graduates with companies that may include its clients.

08:09 EDT ODP Corporation board determines to maintain B2B, B2C businesses - ODP Corporation announced that its board of directors completed its previously announced review of the public and private non-binding proposals received by the company to acquire its consumer business, including the Office Depot and OfficeMax retail stores business and its direct channel business, officedepot.com. Following the completion of that review, the board of directors unanimously determined it is in the best interests of the company and its shareholders not to divest the consumer business at this time. In reaching its conclusion, the board was assisted by its financial and legal advisors, and its process included further discussions of the non-binding proposals with the potential buyers to ascertain additional details about the proposed terms and conditions. It also consisted of evaluating the expected value to the company of such proposals, taking into account the proposed structure, economic terms, certainty, expected timing and potential regulatory requirements. Further, due to current market conditions, the board also determined not to resume the company's previously announced potential public company separation at this time and instead to maintain all of its businesses under common ownership. That separation process had been put on hold earlier this year pending evaluation of potential opportunities to divest the company's consumer business.

08:07 EDT Kaleyra set to join Russell 3000 Index - Kaleyra is set to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, according to an updated list of preliminary additions posted June 17.

08:06 EDT Ashford Hospitality reports May RevPAR up 74.9% year-over-year - Ashford Hospitality reported preliminary portfolio occupancy of 72% for the month of May with an average daily rate -ADR - of approximately $185, resulting in RevPAR of approximately $132, an approximate increase of 74.9% versus May 2021 and an approximate decrease of 6.8% versus May 2019. Additionally, Hotel Net Income was $18.9M. Comparable Hotel EBITDA was $36.9M for the month of May, an approximate 156% increase over May 2021's Comparable Hotel EBITDA of $14.4M. April preliminary portfolio occupancy was 74% with an ADR of approximately $182, resulting in RevPAR of approximately $134. This RevPAR result represents an approximate increase of 98.6% versus April 2021 and an approximate decrease of 6.7% versus April 2019. April and May Comparable Hotel EBITDA was $73.3M vs. $55.9M Comparable Hotel EBITDA for the entire 1Q22.

08:05 EDT Reliance Global expands network to over 30 insurance carriers nationwide - Reliance Global Group has expanded its network to include more than 30 insurance carriers nationwide. In addition, the Company is now licensed to sell policies in 49 states.

08:05 EDT Aveo Pharmaceuticals announces NCCN elevated FOTIVDA to category 1 status - AVEO Oncology announced the National Comprehensive Cancer Network, NCCN, has elevated FOTIVDA to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. "Category 1 is the highest Category recommendation offered by NCCN, which is based on strong clinical evidence and perception of the product among the NCCN Panel Members. The NCCN guidelines are recognized and followed by both academic and community oncologists when selecting appropriate therapeutic options for their patients," said Michael Bailey, president and chief executive officer of AVEO. "This year we presented encouraging long-term, progression free survival and overall survival follow-up data from the Phase 3 TIVO-3 study. These new data demonstrate the durability of FOTIVDA's anti-tumor activity which has translated into an improving OS hazard ratio."

08:05 EDT Landos Biopharma appoints Gregory Oakes as president, CEO - Landos Biopharma (LABP) announced that Gregory Oakes has been named President and CEO, and has been appointed to the Landos Board of Directors, effective immediately. Tim Mayleben, who has been serving as interim President and CEO since November 2021, will continue to serve as a member of the Company's Board of Directors. Oakes most recently served as President, North America, Executive Vice President and member of the Executive Committee of Vifor Pharma (GNHAY).

08:03 EDT Protara Therapeutics announces departure of CFO - Protara Therapeutics announced that Blaine Davis, Chief Financial Officer, CFO, has informed the Company that he will be leaving to pursue other opportunities. His last day at the Company will be July 15, 2022. Davis' departure is not related to Protara's operations, financial reporting or controls. As of March 31, 2022, the Company had cash, cash equivalents and investments of $119M expected to fund operations into mid-2024.

08:03 EDT AbbVie submits sNDA to FDA for atogepant - AbbVie announced that it has submitted a supplemental New Drug Application for atogepant to the U.S. FDA to support the preventive treatment of chronic migraine in adults. If approved, atogepant would be the first gepant approved for the broad indication of the preventive treatment of migraine, including episodic and chronic. The sNDA submission includes data from the pivotal Phase 3 PROGRESS trial in patients with chronic migraine, which supplements the existing data in episodic migraine. People living with chronic migraine experience headaches for 15 or more days per month, which, on at least eight of those days per month, have the features of migraine.

07:57 EDT LiveOne raises annual savings target to over $21.5M - LiveOne expects to have completed the repurchase of approximately 1.2M shares of its common stock for approximately $1M under the current portion of its stock repurchase program. The authorization to repurchase will expire on January 31, 2023. LiveOne has settled over $2M in payables in the current 2023 Q1. The company currently has cash and cash equivalents totaling approximately $14M. As part of LiveOne's plan to focus on generating cash from operations on a consolidated basis, LiveOne is implementing additional cost and expense reductions from both operations and corporate overhead which is anticipated to increase the previously implemented annual cost savings to a total of over $21.5M in its FY23.

07:55 EDT 9 Meters Biopharma trading halted, news pending

07:53 EDT CalAmp partners with assured Techmatics for ELD solution - CalAmp announced a new partnership with transport and compliance leader, assured Techmatics. Together with CalAmp's edge computing devices, the company will offer assured Techmatics' apollo Electronic Logging Device solution to commercial and public fleet operators, enabling them to capture and log critical data necessary for regulatory compliance. apollo ELD has been approved by the U.S. Federal Motor Carrier Safety Administration for interstate and intrastate commerce across America, by a third-party body accredited with the Minister of Transport for Canada and by the Secretaria de Comunicaciones y Transportes for Mexico.

07:51 EDT Ebix provides clarifications on nature, metrics of EbixCash businesses - Ebix provided clarifications related to nature and metrics of businesses and brands that underlay its overall EbixCash business. Gift Card Sales - Ebix clarified that EbixCash gift cards are sold to Corporate clients only for their employees, partners, affiliates or distribution network. Gift card sales to Corporates could have a different revenue treatment by EbixCash vs. the Corporate. For example, a $100 value card is recorded as $100 in gross revenue by EbixCash while possibly getting recorded between 20 to 40 cents in net revenue by the corporate agent, who provides the card to its corporate network. Per EbixCash's contract with issuing Banks, gift cards can only be sold through Corporates approved by the Banks, to their Corporate network after a mandated Know Your Customer onboarding process. Per EbixCash's contract with issuing Banks, Gift cards cannot be sold through just any EbixCash franchisee or retail outlet. Gift cards can only be procured and activated through EbixCash, once the gift cards have been associated with an approved Corporate entity, and only after a KYC approval for the Corporate has been granted by the Reserve Bank of India. The same activation process also applies for each affiliate network entity associated with the Corporate customer. The core functionality, usage, interfacing with vendors and servicing of the card is handled by the Banks, gateway providers, banking technology framework etc. and not by EbixCash. EbixCash or Ebix does not have any direct or indirect connection with any of its franchises, corporates or their Directors or employees. EbixCash App Downloads of 3.74 million plus - To support the various verticals and sub-brands of EbixCash's travel, forex, payments, ticketing, remittance, bus exchange, healthcare businesses etc., EbixCash has developed a wide spectrum of highly focused B2B and B2C apps available via the Google Play Store, the Apple App Store or as html browser plugins. Though May 31, 2022 over 3.74 million downloads of these EbixCash Apps have happened. While EbixCash has achieved substantial total downloads of its spectrum of apps, download metrics are not a core objective for the Company, as the Company is principally focused on providing its services digitally on computers via custom applications built specifically for B2B channel end users. The Company does pursue a direct-to-consumer channel however that is currently accomplished primarily through providing digital technology and services to approximately 650,000 retail locations across South-east Asia. These "phygital" EbixCash outlets are designed to provide "last mile" digital solutions to a prospective base of hundreds of millions of people across the length and breadth of South east Asia. EbixCash is building visibility and brand loyalty with this large base of customers as the Indian economy continues to grow and modernize. Accordingly, EbixCash is differentiated by its growing array of services and profitable B2C strategy versus other market participants that continue to report substantial losses from their efforts to build viable long term businesses. EbixCash WorldMoney Offices - As a result of Covid-19 pandemic shut-downs and as a part of its ongoing cost rationalization efforts, EbixCash elected to close a few EbixCash WorldMoney Forex offices and relocate them to higher traffic locations after securing requisite RBI approvals which are on file. EbixCash WorldMoney outlets are licensed by the RBI to exclusively provide foreign exchange services and thus are not able to sell domestic pre-paid gift cards. Following RBI approval on August 17th 2020, the EbixCash WorldMoney Andheri East Office at Sterling Centre, Mumbai was relocated to 7th Floor Surkasha Ace, Andheri East, Unit 701 also in Mumbai. The EbixCash WorldMoney Bangalore Forex Office located at Jayanagar was merged with existing RBI licensed EbixCash WorldMoney forex branches at Indiranagar and Malleshwaram in Bangalore. Accordingly, the Jayanagar office lease was terminated on July 20, 2020. RuPay, Master Card and Visa - EbixCash has long-standing, symbiotic relationships with each of the three leading credit card brands which include joint marketing initiatives to drive increased reach and business growth. EbixCash is currently engaged in a variety of joint marketing initiatives with its credit card partner which include joint advertisements in magazines, on billboards, on bus shelters and other high-traffic locations across many Indian cities, in addition to social media and web site branding, etc. These programs can include celebrity social media visibility, such as recent social media exposure for the EbixCash Globetrotter Travel Card by the Captain of the India Cricket Team via the Mastercard Network.

07:48 EDT Alabama State University launches Draganfly drone technology course - Draganfly announced that Alabama State University is offering the Draganfly Drone Technology Course through ASU's Division of Continuing Education. he program provides an introduction to unmanned aerial vehicles and explores advanced topics including regulations, airspace operations, and navigation. Draganfly's Drone Technology Course includes a Federal Aviation Administration Part 107 drone preparation course. To fly drones under the FAA's Small Unmanned Aircraft Systems Rule, a Remote Pilot Certificate must be obtained.

07:45 EDT Acadia Pharmaceuticals down 30% after FDA AdCom vote against Nuplazid - Shares of Acadia Pharmaceuticals are down about 30% at $13.69 in pre-market trading after the company announced a negative outcome of FDA Advisory Committee for NUPLAZID for the treatment of Alzheimer's Disease Psychosis.

07:44 EDT Hisamitsu America launches Salonpas Pain Relieving Flex Patch Lidocaine 4% - Hisamitsu America announced the availability of the Salonpas Pain Relieving FLEX Patch Lidocaine 4% featuring thin, flexible, and highly adhesive patch technology. The new Salonpas Pain Relieving FLEX Patch Lidocaine 4% is available now at select retailers and will be available at retailers nationwide this fall.

07:41 EDT Wellbeing Digital names Natalie Dolphin as VP, marketing, investment relations - Wellbeing Digital Sciences announced the appointment of Natalie Dolphin as the Vice President of Marketing and Investment Relations. Prior to joining Wellbeing, she served as the Director of Marking at MagicMed Industries subsequently, acquired by Nasdaq listed Enveric Biosciences Inc., where she held the same title. As part of the executive leadership team, Natalie will be responsible for overseeing the planning and execution of Wellbeing's North American marketing and investment relations strategy.

07:38 EDT Atlas Technical Consultants releases inaugural ESG report - Atlas Technical Consultants announced that it has released its inaugural sustainability report, highlighting our Environmental, Social, and Governance, ESG, strategy and corresponding 2030 goals to meet its commitment to the UN Sustainable Development Goals, SDGs, and Atlas' heart-led values and purpose. Key Highlights of the report include: Completion of a full ESG strategy for Atlas and setting metrics and targets for internal monitoring and external reporting on ESG; Established a Nominating, Corporate Governance and Sustainability Board Committee, and the ESG Executive Steering Committee; Completion of the first carbon footprint inventory; Appointment of the first Chief Diversity Officer responsible; Launch of the first Diversity, Equity & Inclusion Council, and seven employee resource groups.

07:35 EDT Whole Earth Brands announces global strategic ESG goals for 2030 - Whole Earth Brands announced 12 strategic, measurable goals that will guide the company's environmental, social, and governance, ESG, framework through the year 2030. Centered on three pillars - producing sustainably, supporting thriving workers and communities, and enabling healthier lifestyles - the Whole Earth Brands ESG framework seeks to create a positive impact on a number of material topics related to the sourcing, production, and use of our products, including climate, packaging, natural resources, livelihoods, diversity and inclusion. The goals include a 25% absolute reduction in Scope 1 & 2 emissions in owned facilities from the company's 2021 baseline, as well as packaging all products in reusable, recyclable or compostable materials, and a commitment to verified responsible sourcing of key ingredients across our global supply chain. "As we have stated for some time now, the Whole Earth Brands ESG vision is to bring goodness to people and to the planet, and we believe these 12 goals set clear, tangible targets that deliver on this commitment in a defined and attainable timeline," said Albert Manzone, Chief Executive Officer of Whole Earth Brands. "Strong ESG governance underlies all three of our pillars and is fundamental to our overall framework. These 2030 goals make Whole Earth Brands a better company today and provide us a roadmap for how to become a stronger one tomorrow."

07:34 EDT Owens Corning to acquire spray foam manufacturer Natural Polymers, no terms - Owens Corning announced that it has signed an agreement to acquire Natural Polymers a manufacturer of spray polyurethane foam insulation for building and construction applications, based in Cortland, Illinois. The transaction is subject to regulatory approvals and other customary conditions and is anticipated to close in the third quarter. "This acquisition advances Owens Corning's strategy to strengthen our core building and construction products and expand our addressable markets into higher-growth segments," said Todd Fister, president of Owens Corning's Insulation business. "Natural Polymers' proven technology enables us to offer our customers a more diversified insulation product portfolio and solidify our commitment to provide long-term, sustainable solutions." Natural Polymers is dedicated to the development of high-quality products and systems, offering some of the lowest-volatile organic compound products available in the spray foam industry today. Many of the business' products are GREENGUARD Gold Certified by Underwriter's Laboratories - a third party standard set to help reduce indoor air pollution and the risk of chemical exposure. Natural Polymers expects to deliver sales of approximately $100M in 2022. The business has demonstrated a strong track record of above-market growth and is expected to continue to achieve double-digit growth over the next several years. Upon close, Mr. Brown will join Owens Corning in an innovation leadership role. Financial terms of the deal were not disclosed.

07:32 EDT Bioventus amends CartiHeal acquisition structure - Bioventus announced that it has entered into an amendment to the Option and Equity Purchase Agreement for its pending acquisition of CartiHeal. The Amended Acquisition Agreement reduces the closing payment to $50M from the original $315M that was previously agreed. The remaining $215M of the purchase price will instead be paid to CartiHeal stockholders upon the earlier of the achievement of certain milestones or the occurrence of certain installment payment dates. The Deferred Amount will be paid in five tranches commencing in 2023 and ending no later than 2027. Bioventus will pay interest on each tranche of the Deferred Amount, at a rate of at 8% annually, until such tranche is paid. Additionally, the approximately $135M payable to CartiHeal's stockholders upon the achievement of $100M in trailing twelve-month sales will now be payable upon the achievement of $75M in trailing twelve-month sales. Bioventus expects the acquisition to close by the end of July 2022, subject to closing conditions, with an up-front payment to CartiHeal's stockholders of approximately $108M. The Company intends to finance the payment due at closing with additional debt. The Company is finalizing an amendment to its existing Credit and Guaranty Agreement to increase its current Term Loan to facilitate the closing of the acquisition. The payments of the Deferred Amount are anticipated to be made through the Company's free cash flow and expansion of its existing credit facility.

07:32 EDT Ingersoll-Rand appoints Kathryn Freytag as CIO - Ingersoll Rand appointed Kathryn Freytag as vice president and chief information officer, or CIO, reporting to Vikram Kini, CFO. Freytag will serve as part of Ingersoll Rand's extended executive leadership team.

07:30 EDT Biogen reports grant of European patent for Tecfidera - Biogen announced that the European Patent Office has granted a patent that expires in February 2028 related to Tecfidera. The patent, EP 2 653 873, is directed to treating multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European Medicines Agency recommended maintenance dose for Tecfidera. Patent EP 2 653 873 was granted from a divisional patent application of European Patent No. 2 137 537 and includes amended claims, which the European Patent Office Examining Division determined were allowable under the relevant provisions of the European Patent Convention. Biogen expects the patent to be published in the European Patent Bulletin in the coming weeks.

07:27 EDT AstraZeneca: PROpel trial shows LYNPARZA and abiraterone improve rPFS in mCRPC - Results from the PROpel Phase III trial showed that LYNPARZA, olaparib, jointly developed and commercialized by AstraZeneca (AZN) and Merck & Co (MRK)., known as MSD outside the US and Canada, in combination with abiraterone significantly improved radiographic progression-free survival versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations. The results, showing the combination reduced the risk of disease progression or death by 34% versus abiraterone alone based on a hazard ratio of 0.66; 95% confidence interval are now published in the New England Journal of Medicine Evidence. Prostate cancer is the second most common cancer in male patients, causing approximately 375,000 deaths in 2020.1 In clinical trial settings, overall survival for patients with mCRPC is approximately 3 years, while in the real-world setting this is shorter.2-5 Approximately half of patients with mCRPC may receive only one line of active treatment, with diminishing benefit of subsequent therapies.6-10 HRR gene mutations occur in approximately 20-30% of patients with mCRPC.3,11

07:24 EDT Parsons appoints Tim Schmitt to executive leadership team - Parsons Corporation has announced the promotion of Tim Schmitt to its executive leadership team, effective Aug. 1, 2022. Schmitt joined Parsons in 2018 through the company's acquisition of Polaris Alpha and has served as chief development officer since that time. In his new role, Schmitt will continue serving as chief development officer, leading Parsons' robust merger and acquisition program and overseeing the corporation's strategy and market research efforts.

07:21 EDT Pierre Lassonde sells 1M Rubicon Organics shares - Pierre Lassonde announced that on June 20, 2022, Mr. Lassonde sold common shares of Rubicon Organics in an amount of 1,000,000 Common Shares. The Common Shares were sold to the Chair of the Board of Directors of Rubicon, Julie Lassonde, and occurred through the facilities of the TSX Venture Exchange at a price of C$0.77 per Common Share, for aggregate consideration of C$770,000. As of March 2, 2021, the date of Mr. Lassonde's previously filed Early Warning Report, Mr. Lassonde owned, directly or indirectly, or exercised control or direction over 5,427,974 Common Shares and 1,284,587 Common Share purchase warrants of Rubicon, with each Warrant entitling the holder to purchase one Common Share. The 5,427,974 Common Shares represented approximately 13.79% of the total number of issued and outstanding Common Shares as of March 2, 2021. As of June 21, 2022, after the sale of 1,000,000 Common Shares, Mr. Lassonde now owns, directly or indirectly, or exercises control or direction over, 5,715,413 Common Shares and 284,587 Warrants. The 5,715,413 Common Shares represent approximately 10.21% of the total number of issued and outstanding Common Shares, resulting in a 3.58% change to Mr. Lassonde's Common Share holdings since March 2, 2021.

07:19 EDT Sangoma Technologies announces normal course issuer bid - Sangoma Technologies announced that the Toronto Stock Exchange has accepted a notice filed by the Company of its intention to make a Normal Course Issuer Bid with respect to its common shares. The notice provides that Sangoma may, during the 12-month period commencing June 23, 2022 and ending no later than June 22, 2023, purchase up to 1,071,981 Shares, representing 5% of the total number of 21,439,632 Shares outstanding, through the facilities of the TSX, the NASDAQ Global Select Market or alternative Canadian trading systems. Shares will be acquired under the NCIB at the market price and will be purchased for cancellation. The average daily trading volume of the Shares on the TSX for the most recently completed six calendar months is 27,047. Pursuant to TSX policies, daily purchases under the NCIB will be limited to 6,761 Shares, representing 25% of the ADTV, subject to certain prescribed exceptions.

07:17 EDT Constellium says all voting items adopted at Annual General Meeting - Constellium held its Shareholders' Annual Ordinary General Meeting on June 10, 2022 in Paris, France. All voting items presented to the General Meeting were adopted, including the annual accounts for 2021 and the appointment of Directors. Mr. Emmanuel Blot was appointed as a new Non-Executive Director to the Company's Board of Directors for a term of three years. Ms. Martha Brooks and Ms. Lori Walker were re-appointed to the Company's Board of Directors for a term of three years. As previously announced, Mr. Jean-Christophe Deslarzes was appointed as the new Chair of the Board, succeeding Mr. Dick Evans.

07:15 EDT Barnes Group CEO Patrick Dempsey to switch roles, Thomas Hook to succeed - Barnes Group announced that its board of directors has appointed Thomas Hook as president and CEO, effective as of July 14. Patrick Dempsey, who began a leave of absence on March 8 from his position as president and CEO of the company to address health matters affecting an immediate family member, will transition to the newly created role of executive vice chairman of the company until his retirement on December 31 to help effect a smooth leadership transition. Dempsey is expected to continue serving as a member of the company's board of directors following his retirement as executive vice chairman of the company. Julie Streich, whom the company appointed on March 8 as Interim CEO during Dempsey's leave of absence, will remain in that position through July 13 and will continue to serve as the company's CFO thereafter.

07:14 EDT ADMA Biologics announces addition to Russell 2000 Index - ADMA Biologics announced that the Company will be added to the Russell 2000 Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

07:13 EDT Tilt Holdings partners with Last Prisoner Project - TILT Holdings announced a partnership with Last Prisoner Project, a nonprofit organization dedicated to facilitating clemency, expungement and successful re-entries for individuals with cannabis convictions. As part of the agreement that will roll out throughout the year, TILT and Last Prisoner Project will build strategic initiatives that engage across all subsidiaries-Commonwealth Alternative Care, Standard Farms and Jupiter Research-as well as within the communities they serve. "I believe that all legal cannabis operators have an obligation to correct the injustices made by prejudicial laws," said TILT CEO Gary Santo. "Cannabis has been largely decriminalized for several years now, and we need to do our part to help bring freedom to those disproportionately impacted over the past 40-years. The Last Prisoner Project works diligently to address the systemic issues behind cannabis inequality, and TILT shares a similar vision of rightful freedom and equity for all those that have been unjustly impacted by cannabis laws." The Last Prisoner Project is a network of cannabis industry leaders, policy and education experts, and social justice leaders dedicated to fostering restorative justice for those incarcerated for cannabis offenses.

07:11 EDT Southwestern Energy announces $1B share repurchase program - Southwestern Energy announced that its board of directors authorized a share repurchase program, under which the company is authorized to repurchase up to $1B of its outstanding common stock beginning immediately and continuing through and including December 31, 2023. Based on current strip prices and market conditions, the company expects to be able to execute on the full amount of the program while also achieving its target 1.5x to 1.0x leverage ratio range by the end of 2022 and target $3.5B to $3B debt range by the end of 2023

07:11 EDT Altus Power set to join Russell 2000 Index - Altus Power is set to join the Russell 2000 Index at the conclusion of the 2022 Russell indexes reconstitution period, which becomes final after the close of the US equity markets on Friday, June 24.

07:11 EDT Cronos Group, Ginkgo Bioworks announce achievement of THCV equity milestone - Cronos Group (CRON) and Ginkgo Bioworks (DNA) announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin, THCV, a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. "Continuing to hit these productivity milestones in partnership with Ginkgo fuels our innovation pipeline focused on creating borderless products utilizing rare cannabinoids that amplify and differentiate the consumer experience," said Mike Gorenstein, Chairman, President and CEO of Cronos. "We are excited about the possibilities that THCV is expected to give us and look forward to getting more products with rare cannabinoids into market."

07:09 EDT BeiGene announces CDE acceptance of tislelizumab sBLA - BeiGene announced that the Center for Drug Evaluation, or CDE, of the China National Medical Products Administration, or NMPA, has accepted a supplemental biologics license application, or sBLA, for the company's anti-PD-1 inhibitor, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.

07:07 EDT Universal Stainless resumes operations at Bridgeville, PA melt shop - Universal Stainless & Alloy Products reported that operations at its Bridgeville Electric Arc Melting facility resumed in May as anticipated and have now returned to full operating capacity following a metal spill that occurred in April. The spill was caused by a breakthrough at the bottom of a furnace shell. No one was injured and there was no environmental impact. All other operations continued to function normally and there were no near term interruptions to product delivery schedules.

07:07 EDT Tonix announces publication of paper on effects of magnesium - Tonix Pharmaceuticals announced the publication of a paper, entitled "Impact of Magnesium on Oxytocin Receptor Function," in the journal Pharmaceutics, that described results from a research team led by Professor David Yeomans. The paper includes data showing the enhancing effects of magnesium, Mg2+, on the activity of intranasal oxytocin in an animal model of craniofacial pain. The Mg2+ enhanced formulation of intranasal oxytocin is the basis for the Company's TNX-19002 drug candidate in development to prevent migraine headaches in chronic migraineurs, and TNX-29002 which is in development to treat hyperphagia in adolescent and young adult patients with Prader-Willi syndrome. "This new paper further evidences the important role Mg2+ plays in the effect of oxytocin on pain reduction both in vitro and in vivo in an animal model of head pain," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Prior to this work, studies of intranasal oxytocin on pain yielded inconsistent results because the analgesic effect of oxytocin decreased with higher doses, a phenomenon called 'high dose inhibition' or colloquially, as an 'inverted U' shaped dose response. Professor Yeomans and his team have shown that adding Mg2+ to intranasal oxytocin reduces or eliminates the 'high dose inhibition', such that analgesia increases with higher doses of oxytocin. Consequently, we expect that the Mg2+ enhanced formulation of intranasal oxytocin in TNX-1900 and TNX-2900 may provide consistent effects to the extent that the Mg2+ component of the formulation reduces or eliminates the high dose inhibition and may also allow for using higher oxytocin doses."

07:07 EDT Xenon Pharmaceuticals on track to initiate XEN1101 Phase 3 program in 2H22 - Xenon Pharmaceuticals announced next steps in its clinical program evaluating XEN1101 for the treatment of patients with focal onset seizures following the completion of an End-of-Phase 2 meeting with the U.S. Food & Drug Administration. The outcome of the EOP2 meeting supports the advancement of XEN1101 into Phase 3 clinical development, and Xenon remains on track to initiate the Phase 3 program in the second half of 2022. The EOP2 meeting was supported by nonclinical and clinical data, including results from the previously completed Phase 1 trials and the positive Phase 2b X-TOLE clinical trial evaluating XEN1101 in adult patients with FOS. The X-TOLE topline efficacy data demonstrated that the primary and secondary seizure reduction endpoints were statistically significant across all three dose groups, with p-values of less than0.001 for the 20 mg and 25 mg groups, and XEN1101 was generally well tolerated. Based on the EOP2 meeting, Xenon and the FDA aligned on key elements of the Phase 3 program to support a New Drug Application submission. Xenon plans to submit an NDA upon completion of the first XEN1101 Phase 3 clinical trial 'X-TOLE2', if successful, and use the existing data package from the Phase 2b X-TOLE clinical trial along with additional safety data from other clinical trials to meet regulatory requirements. Additionally, alignment was obtained with the FDA on key elements of a single Phase 3 clinical trial to pursue an additional epilepsy indication of primary generalized tonic clonic seizures. Xenon plans to initiate two identical Phase 3 clinical trials called X-TOLE2 and X-TOLE3, which are designed closely after the Phase 2b X-TOLE clinical trial. X-TOLE2 is expected to be initiated in the second half of 2022 followed by the initiation of X-TOLE3 and both studies will run in parallel. These multicenter, randomized, double-blind, placebo-controlled trials will evaluate the clinical efficacy and safety of XEN1101 administered as adjunctive treatment in patients with FOS. Approximately 360 patients will be randomized 1:1:1 for once-daily dosing of XEN1101, XEN1101 or placebo in each trial. Eligibility criteria include adults aged 18 to 75 years old taking one to three anti-seizure medications with a seizure frequency of greater than or equal to4 seizures per month at baseline. Patients will undergo an 8-week baseline period to assess seizure frequency and eligibility for randomization, followed by a 12-week double blind period. There is no titration period. The primary efficacy endpoint is the median percent change in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo. Key secondary endpoints include the proportion of patients experiencing greater than or equal to50% reduction in seizure frequency from baseline for XEN1101 versus placebo, MPC at Week 1 compared to baseline to assess the rapidity of seizure reduction and the Patient Global Impression of Change at Week 12. On completion of the DBP in X-TOLE2 and X-TOLE3, eligible patients may enter an open-label extension study for up to three years. In addition, the ongoing X-TOLE open-label extension also continues to generate important long-term data for XEN1101 in FOS. About XEN1101 Phase 3 Plans in Primary Generalized Tonic Clonic Seizures: Following the initiation of X-TOLE2, Xenon plans to initiate a single Phase 3 clinical trial, called X-ACKT, to support potential regulatory submission in PGTCS. This multicenter, randomized, double-blind, placebo-controlled study will evaluate the clinical efficacy and safety of XEN1101 administered as adjunctive treatment in patients with PGTCS. Approximately 160 subjects will be randomized 1:1 for once-daily dosing of XEN1101 (25 mg) or placebo. Eligibility criteria include adults aged 18 to 75 years old taking one to three ASMs with a seizure frequency of greater than or equal to3 PGTCS over an 8-week baseline period. After the baseline period to assess seizure frequency and eligibility for randomization, patients will enter a 12-week DBP. There is no titration period. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the DBP of XEN1101 compared to placebo. Key secondary endpoints include the proportion of subjects experiencing greater than or equal to50% reduction in PGTCS frequency from baseline for XEN1101 versus placebo, seizure freedom and the PGI-C at Week 12. On completion of the DBP in X-ACKT, eligible patients may enter an open-label extension study for up to three year

07:07 EDT ANI Pharmaceuticals, Veeva announce collaboration - ANI Pharmaceuticals (ANIP) and Veeva Systems (VEEV) announced a collaboration to define and operationalize data-driven commercial strategies for ANI's new Rare Disease Business Unit. ANI is using software, data, and services from Veeva to establish the digital foundation for the launch of the business unit's first commercially available product in the U.S.

07:04 EDT Metropolitan Bank hires Jean-Philippe Gerbi as Chief Digital Officer - Metropolitan Commercial Bank announced that the Bank hired Jean-Philippe Gerbi as Senior Vice President and Chief Digital Officer. Mr. Gerbi will report to Dixiana Berrios, Executive Vice President and Chief Operating Officer. He will be responsible for the Bank's digital platforms that support the Bank's position as a leading commercial banking and payment solutions innovator.

07:03 EDT Kellogg to separate its North American cereal and plant-based foods businesses - Kellogg announced that its Board of Directors has approved a plan to separate its North American cereal and plant-based foods businesses, via tax-free spin-offs, resulting in three independent public companies, each better positioned to unlock their full standalone potential. The three companies, whose names will be determined later, would be the following: "Global Snacking Co.", with about $11.4 billion in net sales, will be a leading company in global snacking, international cereal and noodles, and North America frozen breakfast, with iconic, world-class brands and strong underlying growth momentum and profitability; "North America Cereal Co.", with about $2.4 billion in net sales, will be a leading cereal company in the U.S., Canada, and Caribbean, with a portfolio of iconic, world-class brands and compelling opportunities for investment and profit growth; and "Plant Co.", with about $340 million in net sales, will be a leading, profitable, pure-play plant-based foods company, anchored by the MorningStar Farms brand, with a significant opportunity to capitalize on strong long-term category prospects by investing further in North America penetration and future international expansion. The proposed spin-offs are intended to result in tax-free distributions of North America Cereal Co. and Plant Co. shares to Kellogg Company shareowners. Shareowners would receive shares in the two spin-off entities on a pro-rata basis relative to their Kellogg holdings at the record date for each spin-off. "We expect the North America Cereal Co. spin-off may precede that of Plant Co., with both currently targeted to be completed by the end of 2023. The transactions will follow the satisfaction of customary conditions, including reviews and final approval by Kellogg's Board of Directors, receipt of an Internal Revenue Service ruling and relevant tax opinions with respect to the tax-free nature of the transactions, effectiveness of appropriate filings with the U.S. Securities and Exchange Commission, and the completion of audited financials of the independent companies. Capital structures, dividends, governance, and other matters for each business will be announced at a later date. Management is committed to maintaining an investment-grade credit rating for Global Snacking Co. after the separations. In addition, the Company expects to maintain a strong aggregate dividend and return-on-capital profile across the three businesses. The independent dividend and capital structure policies for each business are expected to be competitive relative to their relevant peer sets. The company will begin incurring pretax expenses related to executing the transactions and setting up the companies. To ensure visibility into the ongoing results of the businesses, the company will disclose these up-front costs and exclude them from its adjusted-basis results in its external reporting."

07:02 EDT AES Corp., Clearway Energy and others form U.S. Solar Buyer Consortium - AES Corp. (AES), Clearway Energy Group (CWEN), Cypress Creek Renewables, and D. E. Shaw Renewable Investments, or DESRI, have formed the U.S. Solar Buyer Consortium to support expansion of the domestic solar supply chain and drive the growth of the American solar industry. The consortium has launched a competitive RFP to search for qualified manufacturers who are aligned with the consortium's goals and can commit to a long-term strategic partnership to supply up to 7 GW of solar modules per year starting from 2024.

06:58 EDT NexGen Energy announces Rook I Project EIS - NexGen Energy announced a milestone in the advancement of regulatory approvals for the 100% owned Rook I Project with the submission of the draft Environmental Impact Statement, or EIS, to the Saskatchewan Ministry of Environment, or ENV, and the Canadian Nuclear Safety Commission, or CNSC. The EIS submission included letters of support for the Project from each of the Clearwater River Dene Nation, or CRDN, Birch Narrows Dene Nation, or BNDN, and Buffalo River Dene Nation, or BRDN, which all have also endorsed the Project through the execution of Benefit Agreements with NexGen covering the entire lifespan of the project. The submission of the draft EIS follows the Provincial and Federal Environmental Assessment, or EA, processes that commenced in April 2019 following regulatory acceptance of NexGen's Project Description. The project, located in the uranium rich district of Saskatchewan's southwestern Athabasca Basin, includes underground and surface facilities to support the mining and processing of uranium ore from the Arrow deposit.

06:48 EDT Scorpio Tankers announces purchase of shares by President, Scorpio Holdings Ltd. - Scorpio Tankers announces that the President of the company and Scorpio Holdings Limited, a related party, have purchased common shares of the company in the open market. The President of the company, Robert Bugbee, has purchased 150,000 common shares of the company in the open market at an average price of $33.68 per share, and Scorpio Holdings Limited has purchased 150,000 common shares of the company in the open market at an average price of $34.19 per share.

06:46 EDT Merck reports 'positive' results from Phase 1/2 study evaluating V116 - Merck announced the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company's investigational 21-valent pneumococcal conjugate vaccine, in pneumococcal vaccine-naive adults 18-49 years of age and 50 years of age and older. In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to PNEUMOVAX 23 across age groups. In the Phase 2 part of the study, V116 demonstrated non-inferior immune responses to PNEUMOVAX 23 for all shared serotypes, and superior immune responses for the serotypes included in V116 but not included in PNEUMOVAX 23, based on study-defined criteria. Responses were measured 30 days post-vaccination by serotype-specific opsonophagocytic activity geometric mean titers, a measure of functional antibody activity.

06:37 EDT Gelesis announces additional $15M pre-order for Plenity - Gelesis announced that Ro, a U.S. direct-to-patient healthcare company, has placed a $15M pre-paid order for the company's commercial product for weight management, Plenity. This is in addition to previous Plenity pre-orders from Ro totaling $40M.

06:36 EDT Tremor International to make $25M investment in VIDAA - Tremor International announced that it has entered into a definitive agreement to make a strategic $25M investment in VIDAA, a smart TV operating system and streaming platform, and a subsidiary of Hisense Co., Ltd, preinstalled on a majority of TVs manufactured by Hisense including TVs with the Toshiba brand, and also integrated into dozens of premium original equipment manufacturers. The Investment is expected to close in the third quarter, subject to the satisfaction of customary closing conditions. Tremor intends to fund the investment utilizing existing cash resources.

06:34 EDT Iris Energy provides updated operating & CapEx guidance - Iris Energy re-iterated expected total online operating capacity of 3.7 EH/s by the end of Q3. The expansion from 50MW to 80MW at its Mackenzie site is progressing ahead of schedule, increasing expected total online operating capacity to 4.3 EH/s by the end of Q4. Given current market conditions, the company intends to defer additional major capital expenditure for work beyond the initial 4.3 EH/s of operating capacity to preserve balance sheet flexibility. The company currently has no corporate debt on its balance sheet. Construction remains on schedule for 50MW of operating capacity at each of the Mackenzie and Prince George sites in British Columbia, Canada. Development has progressed ahead of schedule for expansion to 80MW at the Mackenzie site, now expected to be operating by the end of Q4. The company has made $130M of payments in respect of contracted miners above the initial 4.3 EH/s, which are subject to ongoing discussions. While the company continues to target expansion of total operating capacity above 4.3 EH/s, such plans are expected to be delayed and the company will continue to review such plans in light of evolving market conditions.

06:32 EDT Global-e Online to acquire Borderfree unit from Pitney Bowes for $100M - Global-e (GLBE) announced that it has entered into a definitive agreement with Pitney Bowes (PBI) to acquire the company's Borderfree cross-border ecommerce solutions business. Borderfree helps retailers enter new global markets by localizing their domestic website in 200+ countries and territories, simplifying compliance and regulations processing. In addition, the companies will begin a strategic partnership and commercial relationship whereby Pitney Bowes will provide cross-border ecommerce logistics services to Global-e and its clients. In turn, Pitney Bowes clients will receive access to best-in-class cross-border solutions on the Global-e platform. The acquisition and partnership are expected to strengthen Global-e's offering and solutions for large enterprises. Both businesses will benefit from the combination of unique capabilities that will attract marquee retailers from around the world. Global-e will acquire Borderfree for approximately $100M, financed with cash. Borderfree is expected to generate in excess of $40M in revenues in calendar year 2022. The transaction is expected to close during Q3, subject to customary conditions.

06:06 EDT Lennar sees Q3 deliveries 17,000-18,500 - Sees Q3 new orders 16,000-18,000. Sees Q3 average sales price slightly higher than Q2. Sees Q3 gross margin as a percentage of home sales 28.5%-29.5%. Sees Q3 financial services operating earnings $70M-$75M.

06:04 EDT OneConnect plans to arrange batch-conversion of ADSs to ordinary shares - OneConnect announced that it intends to make arrangements to facilitate conversion of its American depositary shares to ordinary shares in connection with the Proposed Listing. The company filed an application on February 28 with The Stock Exchange of Hong Kong Limited in connection with a proposed dual primary listing of Shares on the Main Board of the SEHK by way of introduction. The company wishes to highlight to the investors that the Proposed Listing is still subject to the company obtaining the approval in-principle of the SEHK for the Proposed Listing, and thereafter, the fulfilment of certain conditions under the AIP, including the granting of the final approval for the listing of, and permission to deal in, the Shares on the Main Board of the SEHK by the listing committee of the SEHK. There is no assurance that the AIP will be obtained, or that the final approval for the Proposed Listing will be granted. The Proposed Listing may or may not occur.

05:45 EDT Eli Lilly, Innovent Biologics announces China NMPA approval for Tyvyt sNDA - Innovent Biologics and Eli Lilly announced that the Center for Drug Evaluation, or CDE, of China's National Medical Products Administration, or NMPA, has approved the supplemental new drug application, or sNDA, for Tyvyt in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma, or ESCC.

05:38 EDT India Globalization Capital subsidiary enters IP deal for Alzheimer's candidate - India Globalization Capital announced that one of its subsidiaries reached an intellectual property, or IP, license agreement for a potential Alzheimer's drug development candidate. Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research, or JNCASR, in India, conducted about 10 years of research and discovery work on NMI, or Naphthalene Monoimide, compounds and the role of NMI compounds on neurotoxicity associated with Alzheimer's. Neurotoxicity, which can result from exposure to natural or synthetic substances, causes damage to the brain and the nervous system. In Alzheimer's patients, neurotoxicity is linked to beta amyloid plaques and Neuro Fibrillary Tangles, or NFT. IGC acquired exclusive global rights to the molecule and plans to develop this NMI lead candidate further. IGC is currently in human trials with IGC-AD1 that targets neuropsychiatric symptoms associated with dementia in Alzheimer's. It is currently being evaluated as an Alzheimer's symptom modifying agent. TGR-63, the new molecule, strategically, gives the company a potential disease modifying agent and positions the company to develop a drug that can potentially treat or modify Alzheimer's by targeting beta amyloid plaques.

05:32 EDT Ionis Pharmaceuticals announces topline results from NEURO-TTRansform study - Ionis Pharmaceuticals (IONS) announced topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's (AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, or ATTRv-PN. Eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for the co-primary endpoints of percent change in serum transthyretin, or TTR, concentration and the modified Neuropathy Impairment Score +7, or mNIS+7, a measure of neuropathic disease progression, versus the historical placebo group. Eplontersen also met its key secondary endpoint of change from baseline in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy, or Norfolk QoL-DN, showing treatment with eplontersen significantly improved patient-reported quality of life versus the historical placebo group. In the study, eplontersen demonstrated a favorable safety and tolerability profile with no specific concerns. The study data are consistent with the clinical profile seen across Ionis' other LICA programs, further validating how advancements in the company's LIgand-Conjugated Antisense technology position Ionis to deliver potentially transformative treatments for a range of unmet medical needs. Based on these study results, the companies will seek regulatory approval for eplontersen for ATTRv-PN and plan to file a new drug application with the FDA this year. The data from the 35-week interim analysis will be presented at an upcoming medical meeting later this year.

05:16 EDT Oryx Gaming goes live with Jumpman Gaming - Oryx Gaming, a Bragg Gaming company, announced that its content is now live across Jumpman Gaming's network of UK brands, marking a step forward for its presence in Europe's largest market. The partnership agreement with Jumpman Gaming allows Oryx to provide its exclusive RGS content, including content developed by its in-house studios as well as its premium partners, which collectively offers player-favorite features and jackpots designed to drive engagement and retention.

05:08 EDT Janus Henderson Group announces Ali Dibadj as CEO - Janus Henderson Group (JHG) announced that Ali Dibadj has joined the company as CEO. Additionally, Dibadj has been appointed to the company's board of directors. He succeeds Roger Thompson, CFO, who had served as interim CEO from April 1 to June 20. Thompson will continue in his role as CFO. Dibadj was CFO and head of strategy at AllianceBernstein (AB).